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Abstract 
 
Many pharmaceuticals have attracted the attention of environmental scientists and 
are of concern due to their observed occurrence in surface water, ground water, 
drinking water, sediment, and soil.  Further investigations have considered their 
removal efficiencies in wastewater treatment processes and their ecotoxicological 
effects.  Cytostatics are a class of pharmaceuticals used in the treatment of cancer 
and have the potential to negatively impact the environment. It is hypothesized that 
due to their mode of action, practically all eukaryotic organisms are vulnerable to 
damage, with teratogenicity being the greatest concern at low ng/L levels. This 
thesis will discuss the contributions to this field in the form of 1) development of a 
method for chemical analysis of cytostatics in wastewater, 2) occurrence studies, 
and 3) potential for removal with advanced treatment processes. 
To expand the knowledge on the environmental occurrence of cytostatics and to 
compliment a range of cytostatics for which occurrence data are available, a solid 
phase extraction and HPLC–MS/MS method was established for highly consumed 
cytostatics 5-fluorouracil, cytarabine, and gemcitabine and the human metabolites 
uracil 1-β-d-arabinofuranoside and 2’,2’-difluorodeoxyuridine. Hydrophilic 
interaction chromatography (HILIC), a chromatography for polar analytes in 
aqueous samples, was used to achieve a good retention of the polar analytes. Along 
with the method development, retention mechanisms on the HILIC stationary 
phase were studied.  Both partitioning and adsorption play a role in the retention on 
the tested sulfoalkylbetaine modified silica HILIC column material. The 
contribution of these two processes changes over the 1.6–40% range of water in the 
mobile phase. Although the specific break point is difficult to determine, 
adsorption becomes more significant as the fraction of water in the mobile phase 
decreases below approximately 16%. 
Wastewater from a Swiss hospital was monitored for 5-fluorouracil, gemcitabine 
and 2’,2’-difluorodeoxyuridine (metabolite of gemcitabine). The limits of 
quantification were 5.0, 0.9, and 9.0 ng/L and the maximum concentrations 
detected were 27, 38, and 840 ng/L, respectively. Emission levels within one day 
and over several days were found to correlate with the pharmacokinetic excretion 
pattern and the consumed amounts in the hospital during these days. On average, 
1.1%, 1.4% and 3.7% of the total excreted amounts of the cytostatics 
5-fluorouracil, gemcitabine and 2',2'-difluorodeoxyuridine were found in the 
hospital wastewater, respectively. Due to low recoveries, stability studies were 
performed and showed that the half-lives of the analytes in the raw wastewater are 
very short: 1.0, 0.7 and 2.5 hours, respectively. 
Environmental impact of 5-fluorouracil, gemcitabine and 2’,2’-difluorodeoxy-
uridine seem to be of minor importance, as the environmental risk assessment 
quotients PEC/PNEC are protective (in orders of magnitude of 10-3 - 10-6). 
Nevertheless, cytostatics are a special group of pharmaceuticals with carcinogenic 
potency and until data with specific tests and end-points designed especially for 
this class of pharmaceuticals are available, the precautionary principle should be 
applied. 
To study removal possibilities, sorption to powdered activated carbon was 
investigated. Adsorption is an effective process for the removal of hydrophobic 
substances from water. Employing it as a wastewater treatment process, polar 
compounds may also be simultaneously removed to a certain extent. Laboratory 
scale batch experiments were performed to evaluate the adsorption kinetics and 
isotherm data of 5-fluorouracil and cytarabine on two powdered activated carbons, 
Norit SAE Super and Activated Lignite HOK Super. The results of the adsorption 
characterization were compared with those of two hydrophobic substances, 
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bisphenol A and 17-α-ethinylestradiol, produced with the identical experimental 
conditions and matrix. A dose of 30 mg.L-1 of Norit SAE Super that resulted in 
removal of the two hydrophobic control compounds below 1% was found to 
remove 30 and 65% of 5-fluorouracil and cytarabine, respectively. Influence of the 
solution pH, ionic strength, temperature, and presence of matrix compounds 
competing for the sorption sites was studied on one of the tested powdered 
activated carbons, showing that the extent of the competing compounds’ influence 
is the greatest. Applying a pseudo single-solute isotherm and a concept directly 
linking carbon dose with relative removal of the micropollutant, capacity of the 
powdered activated carbon was successfully predicted for different initial 
micropollutant concentrations.  
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Chapter 1 
 General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is better to know some of the questions than all of the answers. 
           (James Thurber) 
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1 General Introduction 
 
It has been proven and become common knowledge among environmental scientists, as 
well as among a part of the general public, that endocrine disruptor compounds that 
make their way into the aquatic environment are causing shifts in population of fish due 
to the feminization of males (Sumpter, 2008), and that antibiotics in the environment are 
causing an increase in bacterial resistance (Zhang, 2009). But until now, no one has 
confidently stated whether or not cytostatics have an impact on the environment; though 
the potential is there. Cytostatics are designed to damage DNA, inhibit DNA synthesis, 
and interrupt cell replication. They act unselectively on all growing cells and 
furthermore possess a carcinogenic potency which implies that no threshold values for 
lowest effect concentrations can be estimated. It is hypothesized that due to their mode 
of action, practically all eukaryotic organisms are vulnerable to damage, with 
teratogenicity being the greatest concern at low ng/L levels (Johnson, 2008). On the 
other hand, consumption of cytostatics is low compared to consumption of other 
pharmaceutical classes. As an example, the annual consumptions of analgesics 
acetylsalicylic acid, paracetamol, and metamizol reached in 1999 in Land Brandenburg, 
Germany were around 24 000, 7 000, and 5 000 kg/year, respectively, for antibiotics 
roxythromycin, ampicilin, and ciprofloxacin the annual consumption was around 900, 
500, and 400 kg/year, respectively, while for cytostatics 5-fluorouracil, 
cyclophosphamide, and ifosfamide consumption was only 22, 8, and 8 kg/year, 
respectively (LUA BB, 2002). The wastewater concentrations are expected to be the in 
ng/L range, and surface water concentrations presumably under 1 ng/L (Kümmerer, 
2001). This was proven for the two, most studied cytostatics in the environment: 
ifosfamide and cyclophosphamide. Wastewater concentrations up to 146 ng/L were 
measured in Germany (Steger-Hartmann, 1996) and up to 11 ng/L in Switzerland, 
where the surface water concentrations were as low as ≤50 to 170 pg/L (Buerge, 2006). 
The Swiss study concludes that concentrations were orders of magnitude lower than the 
concentrations at which acute ecotoxicological effects have been reported (mg/L) but 
due to lack of knowledge on chronic toxicity and occurrence and effects of metabolites, 
it was not feasible to perform a final risk assessment.  
The cytostatics consumption data from University Hospital Aachen, Germany, were 
kindly provided over last six years for the purpose of our study by the hospital 
pharmacy, enabling us to point out the “hot targets” and to follow the trends in the 
prescriptions. It is not known if hospitals act as point sources of cytostatic input into the 
environment. To consider this possibility, the following chapter describes, along with 
consumption and pharmacokinetics, the manner of administration and the trends in 
in-patient or out-patient treatment of oncologic patients. Attention is furthermore paid to 
identify the urinary excreted human metabolites, as they might also be environmentally 
relevant. 
To understand the research needs and to recognize the gaps in the current knowledge, 
the first chapter briefly summarizes the available information relevant to the topic 
“Cytostatics in the environment”.  Chapter 2, which follows this introduction, will later 
list the objectives of this study – the questions that have risen while reviewing the field, 
and to which this thesis will provide the answers. 
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1.1  Cytostatics: general characterization, classification, 
and target selection 
 
Cytostatic drugs are used in chemotherapy of oncological patients, who suffer from 
cancer - a disease of uncontrolled multiplication of the body’s own cells and spread of 
abnormal forms within the body. Chemotherapy, together with surgical excision and 
irradiation, is one of the three main approaches to treat established cancer. Cytostatics 
prevent the growth and proliferation of cells although they are not specific to cancer 
cells. According to their mechanism of action, they can be divided into eight groups: 
DNA synthesis inhibitors, angiogenesis inhibitors, DNA intercalators/cross-linkers, 
DNA-RNA transcription regulators, enzyme inhibitors, gene regulators, microtubule 
inhibitors, and other anti-tumor agents. The Anatomical Therapeutic Classification 
System (ATC), recognized and used by the World Health Organization, groups the 
cytostatics under Class L - Antineoplastic and Immunomodulating Agents according to 
their chemical structures and therapeutic properties (Table 1.1). 
 
Chemotherapy doses are usually computed on the basis of body surface area and are 
expressed in mg/m2. The majority of cytostatic administrations are intravenous and are 
executed at a clinic or hospital. Other ways of administration include intramuscular, 
intraosseous, intralesional, topical, or oral. The trend in cytostatic administration is 
shifting towards increasing oral administration executed at home or external ambulatory 
infusion pumps (e.g. for 7 days) installed at the health-care facility but taken home for 
the time of treatment. Approximately 75% of oncology patients are out-patients, 
receiving the treatment at the oncology wards and leaving for home after the infusion or 
injection is administered (Johnson, 2008; Mahnik, 2007). Those patients may excrete 
part of the cytostatics in the hospital, as the treatment takes up to a couple of hours and 
the pharmacokinetics of some cytostatics is relatively fast. European hospitals use 
around 50 different active substances to treat oncology patients (Johnson, 2008). Table 1.1 
shows the variety of cytostatics used at University hospital Aachen, Germany in 2008. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  Ten cytostatics with the highest consumption at University hospital Aachen, Germany (1 510 beds) in 
2003-2008. 
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 Anatomical Therapeutic Chemical Classification System  
Class L                                                                                               
Antineoplastic and Immunomodulating Agents 
           
L01 ANTINEOPLASTIC AGENTS °/▼ L01CA03 Vindesine     L01XE04 Sunitinib 
 L01A ALKYLATING AGENTS  °°/▼▼ L01CA04 Vinorelbine     L01XE05 Sorafenib 
  L01AA Nitrogen mustard analogues   L01CB Podophyllotoxin derivatives    L01XE06 Dasatinib 
°°°/▼▼▼ L01AA01 Cyclophosphamide  °°°/▼▼▼ L01CB01 Etoposide     L01XE07 Lapatinib 
   L01AA02 Chlorambucil  °°/?▼ L01CB02 Teniposide    L01XX Other antineoplastic agents 
°°/▼▼ L01AA03 Melphalan    L01CC Colchicine derivatives     L01XX01 Amsacrine 
   L01AA05 Chlormethine     L01CC01 Demecolcine  °°/?▼ L01XX02 Asparaginase 
°°°/▼▼▼ L01AA06 Ifosfamide    L01CD Taxanes    L01XX03 Altretamine 
   L01AA07 Trofosfamide  °°/▼▼ L01CD01 Paclitaxel     L01XX05 Hydroxycarbamide 
   L01AA08 Prednimustine  °°/▼ L01CD02 Docetaxel     L01XX07 Lonidamine 
°°/?▼ L01AA09 Bendamustine    L01CX Other plant alkaloids     L01XX08 Pentostatin 
  L01AB Alkyl sulfonates  °/?▼ L01CX01 Trabectedin     L01XX09 Miltefosine 
°/▼ L01AB01 Busulfan   L01D CYTOTOXIC ANTIBIOTICS AND     L01XX10 Masoprocol 
°°/?▼ L01AB02 Treosulfan   RELATED SUBSTANCES     L01XX11 Estramustine 
   L01AB03 Mannosulfan    L01DA Actinomycines     L01XX14 Tretinoin 
  L01AC Ethylene imines  °/▼ L01DA01 Dactinomycin     L01XX16 Mitoguazone 
°/▼ L01AC01 Thiotepa    L01DB Anthracyclines and related   °/▼ L01XX17 Topotecan 
   L01AC02 Triaziquone    substances     L01XX18 Tiazofurine 
   L01AC03 Carboquone  °°/▼▼ L01DB01 Doxorubicin  °°/▼▼ L01XX19 Irinotecan 
  L01AD Nitrosoureas  °°/▼ L01DB02 Daunorubicin     L01XX22 Alitretinoin 
°°/▼ L01AD01 Carmustine  °°/▼ L01DB03 Epirubicin     L01XX23 Mitotane 
   L01AD02 Lomustine     L01DB04 Aclarubicin     L01XX22 Alitretinoin 
   L01AD03 Semustine     L01DB05 Zorubicin     L01XX23 Mitotane 
   L01AD04 Streptozocin  °°/▼ L01DB06 Idarubicin  °/?▼ L01XX24 Pegaspargase 
   L01AD05 Fotemustine  °°/▼ L01DB07 Mitoxantrone     L01XX25 Bexarotene 
   L01AD06 Nimustine     L01DB08 Pirarubicin     L01XX27 Arsenic trioxide 
   L01AD07 Ranimustine     L01DB09 Valrubicin     L01XX28 Imatinib 
  L01AG Epoxides    L01DC Other cytotoxic antibiotics     L01XX29 Denileukin diftitox 
   L01AG01 Etoglucid  °°/▼ L01DC01 Bleomycin     L01XX31 Gefitinib 
  L01AX Other alkylating agents     L01DC02 Plicamycin  °/?▼ L01XX32 Bortezomib 
   L01AX01 Mitobronitol  °/▼ L01DC03 Mitomycin     L01XX33 Celecoxib 
   L01AX02 Pipobroman     L01DC04 Ixabepilon     L01XX35 Anagrelid 
   L01AX03 Temozolomide   L01X OTHER ANTINEOPLASTIC     L01XY Combinations of 
°°°/▼▼ L01AX04 Dacarbazine   AGENTS    antineoplastic agents 
 L01B ANTIMETABOLITES    L01XA Platinum compounds      
  L01BA Folic acid analogues  °°/▼▼ L01XA01 Cisplatin  L02 ENDOCRINE THERAPY 
°°°/▼▼▼ L01BA01 Methotrexate  °°°/▼▼▼ L01XA02 Carboplatin   L02A HORMONES AND RELATED  
   L01BA03 Raltitrexed  °°/▼▼ L01XA03 Oxaliplatin   AGENTS 
°°/▼▼▼ L01BA04 Pemetrexed    L01XB Methylhydrazines    L02AA Estrogens 
  L01BB Purine analogues     L01XB01 Procarbazine    L02AB Progestogens 
   L01BB02 Mercaptopurine    L01XC Monoclonal antibodies    L02AE Gonadotropin releasing 
   L01BB03 Tioguanine     L01XC01 Edrecolomab    hormone analogues 
°/?▼ L01BB04 Cladribine  °°°/?▼ L01XC02 Rituximab    L02AX Other hormones 
°°/▼ L01BB05 Fludarabine  °°/?▼ L01XC03 Trastuzumab   L02B HORMONE ANTAGONISTS AND  
   L01BB06 Clofarabine  °/?▼ L01XC04 Alemtuzumab   RELATED AGENTS 
    L01BB07 Nelarabine  °/?▼ L01XC05 Gemtuzumab    L02BA Anti-estrogens 
  L01BC Pyrimidine analogues  °°/?▼ L01XC06 Cetuximab    L02BB Anti-androgens 
°°°/▼▼▼ L01BC01 Cytarabine  °°/?▼ L01XC07 Bevacizumab    L02BG Enzyme inhibitors 
°°°/▼▼▼ L01BC02 Fluorouracil     L01XC08 Panitumumab     
   L01BC03 Tegafur    L01XD Agents used in  L03 IMMUNOSTIMULANTS 
   L01BC04 Carmofur    photodynamic therapy    L03AA Colony stimulating factors 
°°°/▼▼▼ L01BC05 Gemcitabine     L01XD01 Porfimer sodium    L03AB Interferons 
   L01BC06 Capecitabine     L01XD02 Verteporfin    L03AC Interleukins 
   L01BC52 Fluorouracil, comb.     L01XD03 Methyl aminolevulinate    
   L01BC53 Tegafur, comb.     L01XD04 Aminolevulinic acid  L04 IMMUNOSUPPRESSANTS 
 L01C PLANT ALKALOIDS AND                    L01XD05 Temoporfin    L04AA Selective immunosuppr. 
 OTHER NATURAL PRODUCTS    L01XE Proteinkinase Inhibitors    L04AB Tumor necrosis factor  
  L01CA Vinca alkaloids and analogues    L01XE01 Imatinib    alpha (TNF-α) inhibitors 
°/▼ L01CA01 Vinblastine     L01XE02 Gefitinib    L04AC Interleukin inhibitors 
°/▼ L01CA02 Vincristine     L01XE03 Erlotinib    L04AD Calcineurin inhibitors 
 
 
Table 1.1 Anatomical Therapeutic Chemical Classification System (ATC) of cytostatics. Example of an annual 
consumption and expected emission (based on the consumption, urinary excretion rates, and assumption of 75% 
out-patients) is given for a case of University hospital Aachen, Germany (1 510 beds) in 2008. 
Hospital’s annual consumption: Expected emission:  
°°°  100 - 2 500 g/year ▼▼▼ 12 - 150 g/year 
°°  1 - 100 g/year ▼▼ 0.25 - 12 g/year 
°  0.01 - 1 g/year ▼ 0.0025 – 0.25 g/year 
 no consumption ?▼ urinary excretion data not available 
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Consumption and expected emission ranges for the used drugs are included in the same 
table. The ten cytostatics with the highest consumption at University hospital Aachen in 
2003 - 2008 are shown in Figure 1.1. Significant consumption of 5-fluorouracil makes it 
a suitable candidate for this study. Ifosfamide, gemcitabine, cyclophosphamide and 
cytarabine are the next most used cytostatics; with annual consumption rates slightly 
bellow 1 kg/year. Their consumption reaches only one half or one third of the 5-
fluorouracil consumption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is assumed that the hospital wastewater concentration of the cytostatics depends on 
the amount of each drug excreted by patients via urine, although few cytostatics are also 
excreted by faeces (e.g. doxorubicin, irinotecan, methotrexate, vincristin, and 
docetaxel). Urinary excretion rates of the broad range of cytostatics widely vary, as can 
be seen from Table 1.2.  Beside the variation between the cytostatics, the excretion rates 
for a single active substance shows strong inter-patient variation as it is dependent on 
dose, manner of administration, age,  and renal function of the patient.  For the 
University hospital Aachen, the list of the cytostatics with the highest consumption (Fig. 
1.1) overlaps greatly with the list of compounds with the highest expected emission by 
the hospital (Tab. 1.3). The expected emission was calculated by assuming 25% in-
patient treatment and solely urinary excretion: 
 
 
 
  
 
The target cytostatics of this study were selected from the list of cytostatics with the 
highest emission rates at the University hospital Aachen, Germany (2003-2004), with 
the criterion that for some of them environmental occurrence data existed, while for 
some not. They are three antimetabolites, all of them pyrimidine analogues: 
5-fluorouracil; cytarabine; and gemcitabine. At the beginning of this work in 2004, there 
have been a previously reported study on 5-fluorouracil in hospital wastewater (Mahnik, 
2004), while no occurrence data existed at that time on gemcitabine and cytarabine. 
 
 
 
 
 
 
 
 
 
 
 
Urinary excretion rates of the unchanged drug                                                    
[% of administered drug]                                                                       
         
< 5%  5 – 15%  15 – 25%  25 – 45%  45 – 75%  > 75% 
           
Busulfan 
Carmustine 
Docetaxel 
Epirubicin 
Fludarabine 
Paclitaxel 
Thiotepa 
 Cytarabine 
Dactinomycin 
Daunorubicin 
Doxorubicin 
Fluorouracil 
Gemcitabine 
Idarubicin 
Melphalan 
Mitoxantrone 
Vinblastine 
Vindesine 
 Bleomycin 
Cyclophosphamide 
Dacarbazine 
Irinotecan 
Mitomycin 
Topotecan 
Vinorelbine 
 Cisplatin 
Etoposide 
Ifosfamide 
Vincristine 
 Carboplatin 
Oxaliplatin 
 Methotrexate 
Pemetrexed 
           
Expected emission  by 
the hospital ATC  Drug Consumption [g/year] 
[g/year]  [µg/L] 
       
L01BA01  
L01AA06  
L01BC02  
L01XA02  
L01AA01  
L01BC05  
L01CB01  
L01BC01  
L01BA04  
L01AX04  
L01XA01  
L01XX19  
L01XA03 
 Methotrexate 
Ifosfamide 
Fluorouracil 
Carboplatin 
Cyclophosphamide 
Gemcitabine 
Etoposide 
Cytarabine 
Pemetrexed 
Dacarbazine 
Cisplatin 
Irinotecan 
Oxaliplatin 
678 
908 
2 212 
214 
736 
934 
245 
614 
63 
178 
61 
73 
24 
136 
91 
55 
37 
37 
23 
18 
15 
13 
9 
6 
4 
3 
 9.29 
6.22 
3.79 
2.56 
2.52 
1.60 
1.26 
1.05 
0.86 
0.61 
0.42 
0.25 
0.20 
       
Table 1.2 
Urinary excretion rates of some 
cytostatics (SCM, 2007; Dorr, 1994) 
 
Table 1.3 
Cytostatic drugs with the highest 
expected annual emission in 2008 
by a University hospital Aachen 
(1 510 beds, 14 600 m3/year 
water consumption) and their 
expected emission. Calculations 
are based on the consumption and 
urinary excretion rates known from 
pharmacokinetics, assumption of 
75% out-patient treatment, and no 
degradation of the drug in the 
wastewater. 
Water Consumption [L/year]  
Consumption [g/year] × Excretion [%] × In-patients [%] 
Emission [g/L] = 
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1.2 Target cytostatics: 5-fluorouracil, cytarabine and 
gemcitabine 
1.2.1 Indications and Pharmacokinetics 
Metabolic pathways of the three target antimetabolites are schematically represented in 
figures 1.2, 1.3, and 1.4. 5-Fluorouracil, cytarabine and gemcitabine are pro-drugs that 
require for their anticancer activity intracellular activation to diphosphate or 
triphosphate form. They act by preventing the building blocks of DNA from becoming 
incorporated during the S phase of the cell cycle, causing DNA replication inhibition. 
Gemcitabine is a ribonucleotide reductase inhibitor, cytarabine a DNA polymerase 
inhibitor, and 5-fluorouracil a thymidylate synthase inhibitor. The majority of the 
administered doses do not follow this anabolic pathway but are rather catabolised into 
one or more inactive metabolites that are subsequently urinary excreted. 
 
5-Fluorouracil is applied to patients with carcinoma of the colon, rectum, breast, 
stomach and pancreas (intravenously), as well as active solar keratoses, and superficial 
basal cell carcinoma (topically). Capecitabine, tegafur, and carmofur are oral 5-
fluorouracil drugs.  Elimination of 5-fluorouracil in the human body takes place in the 
liver and other tissues. When administered intravenously (i.v.), elimination half-life in 
plasma varies from 5 to 20 min. A total of 60-90% of the administered dose is excreted 
in urine within 24 h (6 h for unchanged 5-fluorouracil), primarily as α-fluoro-β-alanine 
(approximately 80%) and as unchanged 5-fluorouracil (approximately 10% of the 
administered dose) (Heggie, 1987). However, the excretion of 5-fluorouracil can vary 
from patient to patient, with extreme ranges of 2% or 89% (SCM, 2007; Diasio, 1989; 
Dorr, 1994).  The urinary excretion rate of 5-fluorouracil after administration of 
capecitabine, the oral form of 5-fluorouracil, is only 0.5% (Judson, 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2  Metabolic pathway of 5-fluorouracil in humans (Diasio, 1989), and plot of urinary excretion of ten 
patients as reported by Heggie, 1987: ○ total excreted radioactivity;  ● α-fluoro-β-alanine; ∆ 5-fluorouracil; and 
▲  α-fluoro-ureidopropionic acid.  
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Cytarabine is applied to patients with hematologic malignancies, most commonly acute 
myelogenous leukemia and lymphocytic leukemia in adults. It can be administered 
intravenously (either as a bolus “push” or continuous infusion), intramuscularly or 
subcutaneously. Cytarabine is not orally effective because of extensive and rapid 
deamination within the gut lumen (Dorr, 1994). It is rapidly catabolized to uracil 1-β-D-
arabinofuranoside, which is subsequently eliminated in the urine. Within 24 hours, 80% 
of the administered dose is urinary excreted, of which approximately 90% is uracil 1-β-
D-arabinofuranoside. The elimination of cytarabine is biphasic, with initial plasma half-
life 7 to 20 minutes and terminal half-life of 2 to 3 hours (Hamada, 2002).  
 
Similar to cytarabine, gemcitabine is more potent and the most novel of the three 
antimetabolites, originally synthesized as an antiviral agent. It is used for treating lung 
cancer, pancreatic cancer, bladder cancer, and breast cancer. Gemcitabine can be 
administered intravenously or orally. The elimination is rapid, with a half-life of 
approximately 8 min. The gemcitabine metabolite 2’,2’-difluorodeoxyuridine (dFdU) 
has a long terminal phase, with biphasic elimination kinetics with half-lives between 2.5 
and >24 h (Abbruzzese, 1991). On average, 5% of the total drug is recovered as 
gemcitabine in urine, and it all appears within the first 6 h after treatment, and 60% of 
the administered gemcitabine is excreted as the metabolite 2’,2’-difluorodeoxyuridine 
by the urinary tract within 24 h (Table 1.4). The table further illustrates the excretion 
variability of individual patients that is also typical for other target drugs and shows the 
calculated metabolite-to-drug ratios discussed later in Chapter 4 (Occurrence and 
Stability in Hospital Wastewater). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3  Metabolic pathway of cytarabine in humans (Hamada, 2002). 
 
      ELIMINATION                                                                                    ACTIVATION IN TARGET CELLS 
 
 
              2’,2’-difluoro-               gemcitabine         gemcitabine monophosphate 
              deoxyuridine   
 
          
urinary   
             excretion                                                       
                                        gemcitabine diphosphate 
    
    
    
 
 
                                                                                                                                                 gemcitabine triphosphate 
                                                           
 
 
      ELIMINATION                                                                                    ACTIVATION IN TARGET CELLS 
 
 
     uracil 1-β-D-  -              cytarabine             cytarabine 5’-monophosphate 
arabinofuranoside   
 
        cytarabine 5’-diphosphate 
   
urinary   
             excretion              cytarabine 5’-triphosphate                                      
Figure 1.4 Metabolic pathway of gemcitabine in humans (SCM, 2007) and plot of urinary excretion of eight patients 
with continuous infusion of 1000 mg/m2 gemcitabine for 30 min (Lin, 2004):  
dFdU - 2’,2’-difluorodeoxyuridine; dFdC – gemcitabine. 
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percentage of the total dose in urine                                                     
[%]  
dFdU/GemC      
ratio 
 GemC dFdU TOTAL drug   
 0-6 h  0-6 h 6-12 h 12-18 h 18-24 h Total dFdU  0-24 h  0-6 h 0-24 h 
dose [mg/m2]             
790 1  12 10 7 0 29  30  12 29 
 5  55 - 6 9 70  75  11 14 
 10  74 2 5 5 86  96  7 9 
1 000 5  30 2 5 5 42  47  6 8 
 3  18 3 9 2 32  35  6 11 
 4  66 2 5 1 74  78  17 19 
 7  44 26 0 9 79  86  6 11 
 5  34 27 6 4 71  76  7 14 
             
             
AVERAGE 5  42 10 5 4 60  65  9 14 
MEDIAN 5  39 3 6 5 71  76  7 13 
MINIMUM 1  12 2 0 0 29  30  6 8 
MAXIMUM 10  74 27 9 9 86  96  17 29 
             
 
1.2.2 Physical-chemical properties and impact on environmental behavior and 
analytical procedure design 
The physical-chemical properties determine the behavior and fate of the target drugs in 
the environment. Further, they have a major impact on the design of the analytical 
procedure. The relevant physical-chemical properties are listed in Fig. 1.5. The selected 
cytostatic drugs are highly polar, with the logarithm of the octanol/water partition 
coefficient for the un-ionized solute (log P) between −0.89 and −2.09. Further, they are 
non-volatile and either acidic or basic compounds, but uncharged at pH around 6 (with 
exception of zwitterionic FBAL that was not studied further in this work).  
 
The high polarity and low volatility predetermines that the compounds are likely to stay 
in the water phase and their sorption or partitioning to solids or air is not to be expected 
in high fractions. Occurrence in wastewater is expected, as well as low or no sorption to 
particles or sludge. 5-Fluorouracil was reported to be photo-labile (Alsarra, 2004). 
 
For the solid phase extraction procedure design, the properties imply that the retention 
of all target compounds together with a single procedure at pH 6 is possible. This may 
be achieved using polymeric materials developed specially for retention of polar 
compounds (polymers with a hydrophilic monomer or chemically modified polymers) 
as has been previously reported for 5-Fu and CytR (Kiffmeyer, 1998; Mahnik, 2004; 
Tauxe-Wuersch, 2006), or carbon-based sorbents. Alternatively, two different 
procedures with different sorbent materials and sample pHs could be exploited: an anion 
exchange sorbent for acids at high pH; and a cation exchange sorbent for bases at low 
pH. The pKa values of the target analytes are not compatible with the pKa values of 
common weak ion exchange sorbents and only strong ion exchange materials can be 
considered.  
 
High polarity is also the major issue in the selection of a chromatographic method that 
would be suitable for the target cytostatics and metabolites. A classical approach of 
applying reversed phase chromatography on C18 materials is not conceptually suitable 
for highly polar analytes and another approach has to be selected. 
 
 
 
Table 1.4 Urinary excretion of gemcitabine and its metabolite 2’.2’-difluorodeoxyuridine by eight patients 
(Abbruzzese, 1991). 
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 CYTOSTATIC DRUGS 
    
 5-Fu CytR GemC 
    
 5-fluorouracil cytarabine gemcitabine 
CAS number 51-21-8 147-94-4 95058-81-4 
formula C4H3FN2O2 C9H13N3O5 C9H11F2N3O4 
MW [g/mol] 130.02 243.09 263.07 
Hpc [atm m3/mol] [1] 1.66×10-10 1.57×10-19 1.70×10-17 
solubility [g/L] 12.5[3]  200[4] 51.4 [1] 
Log P[2]  -0.89 -2.09 [5] -1.22 
pKa [2] 8.00 acidic 4.2 basic [5] 3.6 basic 
    
 URINARY EXCRETED HUMAN METABOLITES 
    
 FBAL* araU dFdU 
    
 α-fluoro-β-alanine uracil 1-β-D-arabinofuranoside 2’,2’-difluorodeoxyuridine 
CAS number 3821-81-6 3083-77-0 114248-23-6 
formula C3H6FNO2 C9H12N2O6 C9H10F2N2O5 
MW [g/mol] 107.04 244.07 264.06 
Hpc [atm m3/mol] [1] 1.49×10-10 2.82×10-19 3.06×10-17 
solubility [g/L] 1000 61.2 15.6 
Log P[2] < -2 -1.98 -1.04 
pKa[2] 1.5 acidic, 9.3 basic 9.6 acidic 9.6 acidic 
 
1.2.3 Current state of knowledge on environmental occurrence, effects and fate  
The currently available data on the occurrence of the target cytostatics are limited to one 
of the three drugs, 5-fluorouracil, and are listed in Table 1.4. The levels in wastewater 
from an oncology clinic, connected exclusively to 3 toilets and 3 showers used by 18 
patients reached up to 122 µg/L (Mahnik, 2004). In two other European studies, 
5-fluorouracil was not detected in hospital or municipal wastewater above the limits of 
quantification of the analytical method used (Tauxe-Wuersch, 2006; Yu, 2006). No data 
on the occurrence of cytarabine or gemcitabine in the aquatic environment, or on the 
occurrence of any of the above described urinary excreted human metabolites, are 
available, to our best knowledge.  
 
Tests of the ecotoxicity and genotoxicity for the target cytostatics and their metabolites 
were performed in parallel to this study at the Institute of Hygiene and Environmental 
Medicine of RWTH Aachen by Radka Zounkova (Table 1.5).  
Figure 1.5 Physical–chemical properties of the three selected cytostatics and their major urinary excreted human 
metabolites. (*) α-Fluoro-β-alanine was not included in the analytical method described in the Chapter 3. Data 
sources: estimated using EPI Suite v 3.20 software from US EPA [1]; estimated using ADME Boxes v 2.5 software 
from Pharma Algorithms [2]; and experimental values from (Osol, 1975, p.1079)[3]; (Osol, 1980, p. 1088)[4]; and 
(Romanova, 1996)[5]. 
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Table 1.4 Available occurrence data for the target cytostatics. 
 
 
 
 
Pharmaceuti
cal Sample Analytical method 
LOD/LOQ 
[ng/L] 
Measured 
concentrations 
[ng/L] 
Reference 
5-fluorouracil 
Composite samples of wastewater 
from oncology clinic of Vienna 
University Hospital, Austria 
SPE, 
capillary 
electrophoresis 
1000 / 5000 20 000 - 122 000 (Mahnik, 2004) 
5-fluorouracil 
Composite samples of: 
- wastewater from University 
Hospital of Lausanne, Switzerland 
- WWPT influent 
- WWTP effluent 
- wastewater from residential area 
SPE, 
GC-MS 15 / 50 Not detected 
(Tauxe-Wuersch, 
2006) 
5-fluorouracil 
Grab samples of: 
- WWPT influent 
- WWTP effluent 
SPE, 
GC-MS n.a. Not detected (Yu, 2006) 
      
 
 
The lowest observed effect concentrations (LOEC) of the ecotoxicity tests range from 
micrograms per liter to milligrams per liter and are in general lower then the minimal 
genotoxic concentrations (MGC), which are exclusively in milligrams per liter for all 
compounds. MCG of 5-fluorouracil in the data set of Table 1.5 was not determined 
because cytotoxicity of this compound was higher than its genotoxicity (growth 
inhibition >50%). 5-Fluorouracil is showing the lowest EC50 concentrations in all 
performed tests, except for the algae test, in which gemcitabine is slightly more 
sensitive. Parent cytostatic compounds show higher toxicity than their metabolites. 
 
No observed effect concentrations (NOEC) used later for environmental risk assessment 
(Chapter 4.2.4) were chosen from Daphnia magna reproduction test data in Table 1.5, 
as it was the most sensitive tested system. If NOEC value was higher than the highest 
tested concentration, this concentration was taken as the “worst case” NOEC. 
 
 
ECOTOXICITY TESTS  [mg/L] 
   
  5-Fu CytR GemC FBAL AraU dFdU 
NOEC 0.02 <10 <50 50 > 500 > 500 
LOEC 0.03 10 50 100 > 500 > 500 Pseudomonas putida 
EC50 0.044 17 100 140 > 500 > 500 
        
NOEC 10 20 <10 <25 > 200 20 
LOEC 40 40 10 25 > 200 200 D. subspicatus 
EC50 48 53 45 80 > 200 > 200 
 
       
NOEC 1.0 50 5.0 > 100 > 100 60 
LOEC 5.0 100 50 > 100 > 100 100 Daphnia magna                   acute EC50 15 200 110 > 100 > 100 > 100 
 
       
NOEC 0.01 1.0 > 1.0 > 10 > 10 > 1.0 
LOEC 0.05 3.7 > 1.0 > 10 > 10 > 1.0 Daphnia magna reproduction EC50 0.1 10 > 1.0 > 10 > 10 > 1.0 
 
 
GENOTOXICITY TESTS  [mg/L] 
   
  5-Fu CytR GemC FBAL AraU dFdU 
MGC without MA - 167 167 667 > 667 > 667 umu test                               MGC with MA - 333 42 > 667 > 667 > 667 
 
Table 1.5 Ecotoxicity tests (Pseudomonas putida - bacteria - endpoint growth, Desmodesmus subspicatus - algae - 
endpoint growth rate, Daphnia magna - fresh water crustacean - acute test 48 h - endpoint immobilization, 
reproduction test 21 days - endpoint reproduction), and genotoxicity tests (umu test – minimal genotoxic 
concentrations (MGC) with and without metabolic activation (MA)). (Zounkova, 2010, submitted to Chemosphere). 
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Biodegradability data available from the literature show different degradability of the 
three cytostatics obtained at different conditions, although data are in general not very 
consistent (Table 1.6). While the results of Mahnik et al (2007) and Kiffmeyer et al 
(1998) show complete degradation for 5-fluorouracil within the tested conditions, 
results of Yu et al (2006) show only partial degradation. At high concentrations in 
experiments performed by Kummerer et al (1997), no degradation was reported at all 
within 28 days. 
 
 
 
    5-Fluorouracil Cytarabine Gemcitabine 
concentrations 9 mg/L 4.5 mg/L 7 mg/L 
time 28 days (40 days) 28 days (40 days) 28 days (40 days) 
fate not biodegraded 40% biodegraded                 (85%) after lag-phase of 3 weeks 
42% biodegraded                  
(43%) after lag-phase of 3 weeks 
analysis O2 with oxygen electrode O2 with oxygen electrode O2 with oxygen electrode 
matrix mineral medium in deionised water mineral medium in deionised water mineral medium in deionised water 
Closed bottle test             
(Kummerer, 1997) 
        
concentrations 854 mg/L (175 mg/L) 228 mg/L 1660 mg/L 
time 28 days 28 days 4 days (28 days) 
fate 2% biodegraded (17%) >90% biodegraded  45% biodegraded (50%)  
analysis DOC DOC DOC 
matrix mineral medium in deionised water  (effluent from communal hospital) mineral medium in deionised water mineral medium in deionised water 
Zahn-Wellens test            
(Kummerer, 1997) 
        
concentrations 5 mg/L  12.5 mg/L  
time 2 days 10 days  
fate 92% biodegraded                70% biodegraded   
analysis HPLC-DAD HPLC-DAD  
matrix synthetic sewage synthetic sewage  
remark the higher the initial concentration of 5-Fu the slower the degradation   
OECD confirmatory test   
(Kiffmeyer, 1998) 
        
concentrations 1 µg/L   
time 50 days   
fate 50% biodegraded   
analysis GC-MS   
matrix 1:1000 diluted                   waste activated sludge   
Aerobic batch 
biodegradation           
(Yu, 2006) 
    
concentrations 5 µg/L   
time 24 h    
fate >95% biodegraded   
analysis LSC ([2-14C] 5-Fu )   
matrix  municipal ww from local sewer,     8-18 g/L suspended solids   
Elimination by activated 
sludge      
(Mahnik, 2007)            
    
 
 
 
 
 
 
 
 
 
Table 1.6 Biodegradability of the target cytostatics 
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Chapter 2 
 Objectives 
 
 
 
 
 
 
 
 
 
 
 
 
You can know the name of a bird in all the 
languages of the world, but when you're finished, 
you'll know absolutely nothing whatever about the 
bird... So let's look at the bird and see what it's 
doing - that's what counts. I learned very early the 
difference between knowing the name of something 
and knowing something. 
         (Richard Feynman) 
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2 Objectives 
 
This work aimed at investigating cytostatics in aquatic environment, understanding how 
their consumption and environmental concentrations correlate, and how can they be 
eliminated. The main objectives addressed in this work are: 
 
A: to develop a robust and sensitive analytical method for the analysis of the 
selected cytostatics and their metabolites in wastewater; 
 
B: to apply the analytical method for determination of cytostatic concentrations in 
hospital and municipal wastewater; 
 
C: to asses the environmental risk caused by the selected cytostatics (and 
metabolites); 
 
D: to evaluate the sorption behavior of cytostatics to powdered activated carbon as 
a surrogate for the removal of polar micropollutants and as a potential 
wastewater treatment process. 
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Chapter 3 
Analytical Method Development 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To have a great idea, have a lot of them! 
       (Thomas Alva Edison) 
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3 Analytical Method Development 
 
An analytical method for the target pharmaceuticals in wastewater is a tool 
necessary for any studies requiring the concentration measurements (e.g. stability 
tests or sorption isotherms) as well as for revealing the environmental occurrence 
data or mass flow analysis. The method development for the target compounds 
faces three main challenges: 1) the analytes are very polar chemicals for which 
analysis is generally regarded as difficult; 2) the estimated environmental 
concentrations are very low; and 3) the heavy matrix of the raw wastewater 
interferes with the analysis of the compounds of interest. 
HPLC is nowadays a mature analytical technique, nevertheless its development has 
generally mainly focused on reverse phase (RP) chromatography of non-polar 
analytes, effectively retained on non-polar stationary phases such as C18. HPLC 
retention of highly polar molecules, like the analytes described here, on reverse 
phase materials is by definition not effective. If the octanol/water partition 
coefficient of the molecule (P) is smaller than 1 (or log P < 0), there is not much 
driving force for partitioning of a polar molecule from the polar aqueous mobile 
phase to the non-polar stationary phase. As a consequence, polar molecules pass 
through the non-polar stationary phase with little or no retention, unless they are 
retained by a secondary interaction, e.g. aromatic interaction. Chromatography on 
reversed phase materials modified for retention of polar compounds was previously 
employed for analysis of antimetabolites in environmental (Kiffmeyer, 1998), 
surface wipe (Floridia, 1999), as well as biological samples (Fahmy, 2004). 
Alternative and conceptually more suitable liquid chromatographic techniques are 
hydrophilic interaction chromatography (HILIC), employed previously for 5-Fu in 
plasma and tissue (Pisano, 2005), porous graphitic carbon chromatography, as 
employed for 5-Fu and CytR in plasma (Hsieh, 2007), ion pairing chromatography, 
as used for CytR in plasma (Hsieh, 2007), micellar electrokinetic capillary 
chromatography, as used for CytR and araU in human serum (Houze, 2001) or 
normal phase chromatography, as used for GemC and dFdU in plasma and urine 
(Freeman, 1995). In our method development we considered hydrophilic 
interaction chromatography to be the most suitable approach. Apart from being the 
method of choice for HPLC separation of polar compounds, the high amount of 
organic modifier in HILIC has a positive influence on the sensitivity of mass 
spectrometric detection (Hemstrom, 2006). Hydrophilic interaction chromatography 
was first time referred to under the acronym HILIC by Andrew J. Alpert in 1990. 
The analytes interact with polar stationary phase material that is more polar than 
10-40% aqueous mobile phase. The more polar an analyte the better its interaction 
with the stationary phase. Although the mechanism of retention has not been 
completely elucidated, it was proposed to be partitioning between the dynamic 
mobile phase and a slow-moving layer of water with which the polar stationary 
phase is hydrated (Alpert, 1990). This mechanism was however contradicted 
(Hemstrom, 2006) and is still being discussed. This thesis also contributes to the 
better understanding of the HILIC retention process. 
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3.1 Experimental 
3.1.1 Chemicals and material 
Reference compounds 5-fluorouracil, cytarabine, uracil 1-β-D-arabinofuranoside 
and uridine were purchased from Sigma-Aldrich (Seelze, Germany), and cytidine 
from Fluka (Deisenhofen, Germany). Gemcitabine hydrochloride and 2’,2’-
difluorodeoxyuridine were kindly provided by Lilly Research Laboratories 
(Indianapolis, IN, USA). Isotopically labeled internal standards 13C15N2 uridine and 
15N2 5-fluorouracil were supplied by Dr Ehrenstofer GmbH (Augsburg, Germany), 
13C3 cytarabine and 13C15N2 5’-deoxy-5-fluorocytidine by Toronto Research 
Chemicals Inc. (North York, ON, Canada). SPE cartridges Isolute ENV+ (90 µm, 
1000 mg, 6mL) were supplied by Separtis (Grenzach-Wyhlen, Germany) and 
Bakerbond Speedisk H2O-philic SA-DVB disc cartridges (15 µm, 200mg, 6 ml) by 
Mallinckrodt Baker (Griesheim, Germany). Other tested extraction materials were 
Oasis HLB and Oasis MAX (Waters, Eschborn, Germany), Accubond Evidex 
(Agilent, Waldbronn, Germany), Empore MPC-SD, Bond Elut Certify I , SPEC 
MP1 and SPEC MP3 (Varian, Darmstadt, Germany), Strata X, Strata SAX and 
Strata XC (Phenomenex, Aschaffenburg, Germany), Bakerbond Carbon, 
Bakerbond Speedisk Narc-2 and Bakerbond Speedisk H2O-philic SC-DVB 
(Mallinckrodt Baker, Griesheim, Germany), and ZIC-HILIC SPE (SeQuant, Marl, 
Germany). 
3.1.2 Sample collection 
Hospital wastewater from a Swiss cantonal hospital (415 occupied beds) was 
collected automatically and flow-proportionally between April 30 and May 8, 
2007. Composite samples of approximately 18-hours, were each prepared and 
analyzed in duplicate. The samples were filtered through a 0.7 µm GF/F glass-fiber 
filter (Whatman, Dassel, Germany) and further through a 0.2 µm cellulose acetate 
membrane filter (Sartorius, Goettingen, Germany). Subsequently, the samples were 
stored in glass bottles at -20°C until analysis. For the method development, grab 
samples of hospital wastewater from a University Hospital, Germany (1 510 beds) 
were used.  
3.1.3 Hydrophilic interaction chromatography 
The HPLC system HP1100 (Agilent, Waldbronn, Germany) consisted of a binary 
pump, an auto-sampler and a column thermostat. The separations were performed 
on a 150 × 2.1 mm ZIC-HILIC PEEK column (3.5 µm, 100 Å) from SeQuant 
(Marl, Germany) equipped with a ZIC-HILIC precolumn (20 × 2.1 mm, 5 µm). 
Eluent A was of 30 mM ammonium acetate and acetonitrile (2/3, v/v) and eluent B 
was acetonitrile. The pH of ammonium acetate was not adjusted. The column 
thermostat was set to 35°C, flow rate to 0.2 mL/min and injection volume to 2-6 
µL. An Agilent HP1100 UV detector was used for HILIC method development and 
retention mechanism studies. Standards of 10 mg/L in acetonitrile were monitored 
at wavelengths of 267 nm (5-Fu) and 281 nm (CytR, GemC, araU, dFdU). Toluene 
was used as a void volume marker for calculation of retention factors used in 
Figure 3.1. 
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3.1.4 Solid Phase Extraction 
3.1.4.1 First screening approach 
During the SPE method development, different SPE materials were tested by a 
simple procedure in which 10 mL of spiked tap water (500 µg/L) were percolated 
through a conditioned cartridge and collected. Tap water was before loading 
adjusted to pH 6.3 for the materials Isolute ENV+, Oasis HLB and Strata X, to pH 
2.0 for the materials Bond Elut Certify I, Accubond Evidex, SPEC MP1, SPEC 
MP3, Empore MPC-SD, Speedisk Narc-2, Speedisk H2O-philic SC-DVB and 
Strata XC (retention by cation exchange for basic analytes), and to pH 11.0 for the 
materials Oasis MAX, Speedisk H2O-philic SA-DVB and Strata SAX (retention by 
anion exchange for acidic analytes). Additionally, ZIC-HILIC SPE material was 
tested as above but spiking 5 mL of acetonitrile/water mixture (9:1) with 100 µg/L 
of the analytes. Efficiency of eluting solvent for Bakerbond Carbon was 
determined by spiking 2 mL of eluting solvent with analytes (25 µg/L) and passing 
it through a conditioned cartridge. 
3.1.4.2 Isolute ENV+ method 
Analytes were extracted from 50 mL of wastewater using Isolute ENV+ 1000 mg 
cartridges preconditioned with 15 mL of methanol and 15 mL of 10 mM 
ammonium acetate buffer pH 6.0. After adjusting the sample with acetic acid to pH 
6.0 and spiking 50 ng of labeled internal standards, the samples were transferred 
into 60 mL SPE reservoirs fixed on top of each preconditioned cartridge. The 
wastewater, filtered as described above, was percolated through the cartridges by 
gravity at a flow below 0.3 mL/min. After extraction, the cartridges were washed 
with 3 mL of water and dried until the Isolute ENV+ material presented a uniform 
light orange color. Analytes were eluted with methanol, and 4.5 mL of the eluate 
was evaporated slowly to dryness under a gentle nitrogen stream. Samples were re-
dissolved in 200 µL of HPLC mobile phase at initial composition. 
3.1.4.3 Optional SPE for difficult matrices 
Both materials, Isolute ENV+ and Speedisk H2O-philic SA-DVB, were separately 
preconditioned using 15 mL of methanol and 15 mL of tap water adjusted to pH 
11.2. A Speedisk H2O-philic SA-DVB disc cartridge was connected beneath each 
Isolute ENV+ cartridge. Samples of 50 mL of filtered wastewater were adjusted to 
pH 11.2 with 25% ammonium hydroxide, spiked with 50 ng of labeled internal 
standards and loaded through the reservoirs connected to the Isolute ENV+ 
cartridges. After slow loading (0.3 ml/min) and washing with 3 mL of water 
adjusted to pH 11.2, the two adjacent cartridges were disconnected and dried. The 
Speedisk H2O-philic SA-DVB disc cartridges were eluted with 3 mL of 
methanol:formic acid (98:2). Isolute ENV+ cartridges were eluted separately, as 
described above. The eluates were carefully evaporated in a nitrogen stream, each 
re-dissolved in 100 µL of mobile phase and separately analyzed by different 
HPLC-MS/MS methods. 
3.1.5 Tandem mass spectrometry.  
A triple quadrupole mass spectrometer API 4000 (Applied Biosystems, Foster City, 
CA) with a Turbo IonSpray source was used for MS/MS detection. The detection 
was performed at source temperature 390°C in multiple reaction monitoring 
(MRM) mode with negative or positive electrospray ionization. The analysis was 
separated into two HPLC-MS/MS methods. The HPLC gradient for analytes in 
negative ion mode (5-Fu, dFdU, araU) and respective internal standards (Table 3.1) 
was as follows: 0 min (88% B), 10 min (88% B), 19 min (35% B), 19.8 min (35% 
B), 26 min (88% B) and finished at 37 min. The flux from the column was directed 
by a 6-port Valco valve to the detector (2.6 – 23 min) or discharged to waste. 
Sample injection volume was set to 5 µL. The ion spray voltage and declustering 
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potential of the MS/MS were set to -3.7 kV and -40 V respectively. For the 
analysis of GemC and CytR as well as the two internal standards (Table 3.1), 
positive ion mode was used and following chromatographic gradient was applied: 0 
min (77% B), 2 min (77% B), 10 min (26% B), 12 min (26% B), 20 min (77% B) 
and finished at 30 min. The flux from the column at 4.2 – 30 min was directed to 
the MS/MS. The sample injection volume was set to 2 µL, the ion spray voltage 
and declustering potential were 4 kV and 31 V, respectively. Table 3.1 lists further 
the measured transitions, optimum values of collision energy and collision cell exit 
potential, as well as time segments of the analysis. 
3.1.6 High-resolution mass spectrometry. 
High-resolution MS was performed using the LTQ-Orbitrap mass analyzer 
(Thermo, Waltham, MA, USA). The HPLC system consisted of a Flux Instruments 
Rheos 2200 pump (Flux Instruments AG, Basel, Switzerland) and a PAL 
autosampler (CTC Analytics AG, Zwingen, Switzerland). Chromatographic 
analysis was performed as described above. Ionization was done in the negative 
mode of electrospray with source voltage of 4.5 V and capillary voltage of 25 V. 
Masses of 5-Fu and the identified interfering peak were subjected to chemical 
formula calculator (Thermo Electron, San Jose, CA).  
3.1.7 Quantification,identification and quality control.  
Analyst 1.4.1 software was used for API 4000 instrument control and data 
processing. Quantification was based on 1/x weighted linear regression calibration 
curves of peak area ratio (analyte product ion 1 / internal standard product ion 1) 
versus concentration. Comparison of retention times of internal standard and 
analyte in the same chromatogram was used for identity confirmation. 
Furthermore, two product ions of each analyte and internal standard were measured 
and their ratio was calculated. This was not feasible for 5-Fu in SPE preconcentrated 
wastewater samples due to interference in product ion 2 (see section 3.2.3). 
Calibration standards were measured at the beginning and at the end of each 
sequence, and one spiked real sample or calibration standard were measured  
 
 
product ion 1  
 compound 
time 
segment 
[min] 
   tR        
   [min] 
molecular 
ion  
[m/z] [m/z] CE CXP 
instrumental 
LOD [pg] 
product 
ion 2 
[m/z] 
area ratio of 
two product 
ions 
 
 
  
  
       
5-Fu 5.91 ± 0.22 129.0 59.0 -34 -4 0.48  42.0 0.09 
dFdU 6.14 ± 0.17 262.8 220.0 -16 -10 0.06  111.0 8.4 
15N2 5-Fu 
0 - 12.5 
5.91 ± 0.15 131.0 43.1 -30 -1 n.d.  59.0 29.6 
             
araU 21.18 ± 0.03 242.8 200.0 -14 -10 0.39  110.3 1.9 ME
TH
OD
 1 
  
 E
SI
- 
13C15N2 urd 
12.5 - 22.5 
20.44 ± 0.09 246.0 110.9 -22 -6 n.d.  201.0 1.2 
              
GemC 6.76 ± 0.13 264.0 112.0 38 8 0.03  95.0 3.2 
13C15N2 dFC 
4.2 - 9 
5.33 ± 0.10 249.1 132.7 59 8 n.d.  115.1 7.8 
             
CytR 14.72 ± 0.14 244.0 112.0 23 8 0.09  95.0 5.0 ME
TH
OD
 2 
ES
I+
 
13C3 CytR 
9 - 30 
14.72 ± 0.11 247.1 115.0 23 5 n.d.  97.7 5.8 
              
  
Table 3.1. HPLC-MS/MS parameters for the target substances and their internal standards. Product ion 1 was used 
for quantification. Instrumental limits of detection were estimated from signal to noise ratio (S/N = 3) of a low 
concentration calibration standard in mobile phase. tR - retention time, CE - collision energy, CXP - collision cell exit 
potential, n.d. – not determined.  
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repeatedly throughout the sequence to check for signal stability. Blanks of mobile 
phase with and without internal standards were used to check for possible carry-
over. Instrumental limits of detection were estimated from signal to noise ratios 
(S/N = 3) of low concentration calibration standards in mobile phase. Method 
limits of quantification were estimated from the signal to noise ratio (S/N = 10) of 
a real sample. Run-to-run variations were assessed from 5 injections, day-to-day 
variations over 3 days. Relative SPE recoveries were determined by spiking the 
analytes and internal standards in wastewater prior to SPE. Absolute recoveries 
were determined by spiking the analytes prior to SPE and internal standards 
afterwards, prior to analysis. For the Isolute ENV+ method, the recovery 
experiments were carried out in triplicates. The absolute recovery for the 
combination of Speedisk H2O-philic SA-DVB and Isolute ENV+ were determined 
for two replicates, relative recovery for 6 replicates.     
3.1.8 Safety considerations. 
The handling of hospital wastewater and cytostatic drugs requires safety measures 
for the protection of personnel and the workplace from contamination from 
pathogens and carcinogenic substances. 
 
 
 
3.2 Results and Discussion 
3.2.1 Hydrophilic interaction chromatography.  
Retention of one of the target analytes (5-Fu) by hydrophilic interaction on amino 
and silica columns has been previously reported (Olsen, 2001; Pisano, 2005). 
Nevertheless, 5-Fu has also been used as a void volume marker on an Atlantis 
HILIC Silica column (Grumbach, 2004).Baseline separation is required for 
simultaneous determination when using UV detection. This is feasible for 5-Fu, 
CytR, GemC, dFdU and araU on the tested ZIC-HILIC column. At isocratic 88% 
acetonitrile all peaks can be separated with retention factors k’ of 0.5 – 7.6 and 
resolution greater than 2.4. The elution order follows the Log P pattern, with the 
most polar CytR being retained longest (Figure 3.1), and is the inverse to the 
retention order observed on most RP columns (data not shown). 
 
In Fig. 3.1, the logarithms of retention factors of the target compounds, log k, are 
plotted against the volume fractions of water in the mobile phase, ϕ, in linear as 
well as logarithmic scales. A linear relationship of log k = f(ϕ)would provide an 
evidence for partitioning, while linearity in the log k = f(log ϕ) plot would fit the 
adsorption model (Hemstrom, 2006). The results show linearity of the log–log plot 
with the slope of the function changing at approximately 14% water (Fig. 3.1a). 
The coefficients of determination, r2, of the linear regression at both regions (40–
14% water and 14–1.6% water in the mobile phase) are between 0.9916 and 
0.9996. The observed changes in the retention characteristics at around 14% water 
apply to all five investigated compounds, albeit the change of the slope tends to be 
less pronounced as the polarity of the compounds increase. The ratios of the slope 
of the linear regression below 14% water and the slope of the regression above 
14% water in the mobile phase are 1.2, 1.4, 1.8, 1.8, and 2.5 for cytarabine, uracil 
1-β-D-arabinofuranoside, gemcitabine, 5-fluorouracil, and 2’,2’-difluorodeoxyuridine, 
respectively. The lin–log plots at 1.6–40% water are non-linear (Fig. 3.1b). 
 
 
 
  
34                  Chapter 3               Analytical Method Development                
 
 
 
 
Considering splitting the plot into two regions at around 18% water in the mobile 
phase, it can be observed that the less polar compounds, for which the change in 
the slope of log–log plot was the most evident, show linearity at the region of 
18-40% water in the mobile phase. This indicates that there is a change in the 
retention mechanism as the relative contributions of partitioning and adsorption are 
changing over the range 1.6–40% water, although it is difficult to assign a specific 
break point.  
 
Decreasing the fraction of water below 10% increases the retention times 
dramatically. Though HILIC is defined in 10–40% aqueous mobile phase (Alpert, 
1990), below 10% water the chromatographic interaction in the column is already 
out of the scope of that definition. Nevertheless, applying 100% of acetonitrile did 
not decrease retention. On the contrary, it resulted in retention times larger than the 
tested 420 min for all five analytes. Elution occurred when water was again 
introduced into the mobile phase. This indicates either that the previously bonded 
water molecules are strongly attached to the stationary phase and partitioning into 
the water layer can take place or that in the absence of water there is an interaction 
with the sulfobetaine stationary phase itself. Employed stationary phase of the 
ZIC-HILIC column is based on silica modified with a covalently bound 
zwitterionic polymeric material with a ratio of strong cation to strong anion 
exchange groups one to one, resulting in zero surface charge. The zwitterionic 
3-sulfopropyldimethylalkylammonio inner salt has a good water-binding ability 
(Hemstrom, 2006) that can be exploited in HILIC to create an interactive layer of 
stagnant aqueous phase into which polar solutes might partition. A partitioning 
mechanism in which analytes do not interact directly with the stationary phase but 
partition into the water layer attached to it was proposed for HILIC in 1990 
log (Volume fraction of water)
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lo
g 
k'
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Figure 3.1 
Logarithmic (a) and linear (b) plots 
of log.retention factor (log k’) vs. 
volume fraction of water in ACN / 
30 mM ammonium acetate, as 
mobile phase. 
○ dFdU, ◆ 5-Fu, □ GemC, △araU, 
● CytR 
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(Alpert, 1990). Recently, the evidence was shown that surface adsorption may also 
play a role in retention (Hemstrom, 2006). Our results, presented above, for very 
polar compounds of interest and ZIC-HILIC column confirm this evidence. 
 
It is to be noted, that in this study we do not consider weak electrostatic 
interactions that can take place on a zwitterionic column, although we are aware 
that it might be an oversimplification. With permanently charged stationary phases, 
the electrostatic interactions depend only on the ionization state of the analytes and 
can take place when those are ionized. This is not very likely for the target analytes 
at the working conditions (with exception of 5-Fu, of which less then 10% is 
expected to be negatively charged with the remaining 90 + % uncharged) but 
cannot be excluded. The pKa values listed in Figure 1.5 and used throughout the 
study, refer to aqueous solutions and are, with exception of CytR, software 
predicted. Furthermore exact pH values for the acetonitrile/water mixtures of the 
mobile phases are not known, and thus neither the exact ionization state of the 
molecules. 
 
The effect of the water fraction on the retention was stronger than the influence of 
pH, salt concentration or used organic solvent, acetonitrile versus methanol (data 
not shown). At 90 or 95% acetonitrile, which were the initial conditions of the two 
developed HPLC–MS/MS methods, this effect was so pronounced that it resulted 
in retention time fluctuations due to occasional changes in solvent ratio delivered 
by pumps, operating at the margin of their range (at flow 0.1 mL/min). 
Reproducible retention times were achieved with the same pumps by premixing the 
eluents and increasing the eluent flow to 0.2 mL/min, which only slightly increased 
the theoretical plate height.  
 
Aqueous samples are not suitable for the injection as water is the strongest solvent 
in HILIC. We found that the analysis of such samples is possible, when only a 
small volume (2 µL) is injected. Up to 20 µL of calibration standard solution in the 
initial mobile phase can be injected without deterioration of the peak shapes. For 
the application to wastewater samples we consider an injection volume of 2 to 6 µL 
of SPE extract in the initial mobile phase composition as optimal. 
 
3.2.2 Solid-phase extraction  
The SPE screening test for retention with 10 mL of tap water spiked with analytes, 
collected after percolation through a cartridge and analyzed, showed satisfactory 
results of less than 10% of the spiked amount in the percolate for Isolute ENV+, 
Speedisk H2O-philic SA-DVB, Speedisk H2O-philic SC-DVB, Strata XC and 
Speedisk Narc-2.  
 
The hydroxylated highly-crosslinked polystyrene-divinylbenzene copolymer of 
Isolute ENV+ showed better retention, especially for 5-Fu and dFdU, than 
hydrophilic macroporous poly(N-vinylpyrrolidone-divinylbenzene) copolymer of 
Oasis HLB, as also reported for 5-Fu elsewhere (Tauxe-Wuersch, 2006). Both SPE 
materials, Oasis HLB and Isolute ENV+, are commercially available polymers 
designed to retain a broad range of molecules, including polar ones. Some studies 
have compared the two sorbents with similar or slightly worse results for Isolute 
ENV+ as summarized in a comprehensive overview (Fontanals, 2005). In many 
cases, co-polymeric sorbents with a polar monomer are considered to be more 
efficient at extracting polar compounds (e.g. phenols) than the hydrophobic 
sorbents that are chemically modified with a polar moiety. It has to be noticed that 
many compounds commonly addressed as polar or very polar, for example phenols 
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(log P above 1), are considerably less polar than the studied cytostatics (log P from 
-0.8 to -2.1). Superior performance of Isolute ENV+ in retention of studied 
cytostatics suggests that the retention mechanism characterized by interactions 
between delocalized electrons of the aromatic ring of the sorbent and the π system 
of the analytes is favored in the case of very polar aromatic compounds when 
compared to other noncovalent interactions like van der Waals forces or hydrogen 
bonds. 
 
Before testing retention on the carbon-based sorbent Bakerbond Carbon, a test for 
evaluation of eluting solvents was performed. It has been reported that elution from 
carbonaceous sorbents is difficult due to the strong π-π interactions as retention has 
been shown to be strong for a wide range of compounds (Hennion, 1999). We 
tested methanol, acetonitrile, methylene chloride, tetrahydrofuran, and their 
mixtures and observed that analytes undesirably partitioned from the eluting 
solvent into the carbon material. The most effective was the mixture methylene 
chloride:methanol (8:2) with 2% of formic acid. Still, only two analytes were 
recovered above 20%: dFdU (122%) and araU (63%). No efficient solvent for 
eluting all analytes was found and therefore the material was not considered 
further.  
 
Aside from Isolute ENV+, the tested SPE materials capable to retain the selected 
antimetabolites are the ion exchangers. Using the Isolute ENV+ has the advantage 
of retaining all target analytes with one cartridge. The drawback is a low degree of 
clean-up owing to the ability of the Isolute ENV+ to retain not only a broad range 
of chemicals of interest, but also matrix compounds.  
 
Relative recoveries of target analytes in treated wastewater and hospital wastewater 
with Isolute ENV+ ranged between 79% – 117% and 83% – 125%, respectively. 
Absolute recoveries ranged from 87% to 132% in treated wastewater and from 
72% to 127% in hospital wastewater. Recoveries were verified for spiked 
concentrations of 50 ng/L and 2 µg/L, with no considerable difference. Evaluation 
of recoveries for 50 ng/L of CytR and araU was not possible due to interferences 
(see section 3.2.3).  
 
Although the recoveries of the Isolute ENV+ method are satisfying, we have 
occasionally observed a high ion suppression during MS/MS for all negatively 
ionizable analytes eluting before 10 minutes. Figure 3a shows the extracted ion 
chromatogram (XIC) of 5-Fu product ion 1 in the Isolute ENV+ preconcentrated 
hospital wastewater sample spiked with cytostatics and injected to the HPLC-
MS/MS system. The same sample after a ten-fold dilution was again injected, 
producing a signal of much higher quality and intensity (Figure 3.2b). 
 
For a higher degree of clean-up we tested combinations of Isolute ENV+ with 
Speedisk H2O-philic SA-DVB or with Speedisk Narc-2 at pH 11.2 and 1.3, 
respectively. The Isolute ENV+ on top of the Speedisk H2O-philic SA-DVB proved 
to be the best option. At pH 11.2 the basic compounds were retained uncharged on 
Isolute ENV+ and deprotonated acidic compounds were held by an anion- exchanger 
on Speedisk H2O-philic SA-DVB. Although the absolute recoveries of 5-Fu, GemC 
and dFdU (40 – 79%) in hospital wastewater at spiked concentrations of 600 ng/L 
and 1.8 ug/L are lower compared to the recoveries of the Isolute ENV+ method, the 
matrix causes less ion suppression and the HPLC column is not overloaded. The 
deficiency of this method is a partial retention of dFdU on the Isolute ENV+. The 
internal standard 15N2 5-fluorouracil does not account for this loss, as it passes 
through the Isolute ENV+ at pH 11.2 unretained. Concentrations of dFdU were 
therefore corrected for the value of relative recovery.  
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3.2.3 Mass spectrometry 
In environmental samples of municipal or hospital wastewater we often observed 
an interfering fragment ion of 129.0/42.0 co-eluting, within only a 0.2 minute 
difference, with the most intense 5-Fu transition (5-Fu product ion 2). The presence 
of the interfering substance is evident by comparing the retention times of the 5-Fu 
and the labeled 15N2 5-Fu in the extracted ion chromatogram of the same 
measurement (Figure 3.3). Comparing with the average retention time of the 
standards for calibration or spiked samples measured within the same sequence is 
not feasible, as the retention time of 5-Fu has a deviation of up to 0.22 min. The 
presence of the isotopically labeled internal standards specific to the target analyte 
is in this case crucial not only for quantification but also for confirming the identity 
of the measured signal. High resolution MS analysis (LTQ Orbitrap) with mass 
resolution of 100 000 and a mass accuracy within 5 ppm revealed, that while the 5-
Fu produces a molecular ion of 129.0109 (Δm/m = 2.3 ppm) in negative mode, the 
mass of the interfering molecular ion was 155 ppm higher (Figure 4e, f). Elemental 
composition of the interfering substance (elements in use: 1H, 12C, 14N, 16O, 32S) 
was proposed to be C4H5O3N2 (Δm/m = 11.1 ppm). No matrix interference was 
observed for the 5-Fu transition 129.0/59.0 (product ion 1) and the transition could 
be reliably used for identification and quantification of 5-Fu. The intensity of the 
129.0/59.0 signal is however one order of magnitude lower compared to 
129.0/42.0, which increases considerably the lowest detectable concentration.  
 
Antimetabolites are intentionally designed to closely resemble pyrimidine, purine 
or folic acid so that they can be involved in cell division machinery and can later 
cause its blockage. If the analogues differ only very slightly, their chromatographic 
separation is difficult. Co-eluting peaks in the extracted ion chromatogram of both 
product ions of CytR, 244.0/112.0 and 244.0/95.0, are present in all preconcentrated 
wastewater samples, including WWTP effluent. The interfering substance is a 
naturally occurring nucleoside, cytidine, which is an epimer of CytR. The two 
compounds differ on the sugar moiety at the 2’ position, where 2’-hydroxyl group 
of cytidine is equatorial, while in the case of CytR the group is axial and so in a 
position trans to the 3’-hydroxyl of the sugar, arabinose. The exact masses and 
fragmentation pattern of the two isomers are identical and a small difference in 
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Figure 3.2 
MRM chromatograms  of 5-Fu in: 
a) spiked hospital wastewater 
preconcentrated by Isolute ENV+:  
ion suppression due to insufficient 
sample clean-up; b) same sample 
as above, ten times diluted 
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retention times on the ZIC-HILIC column (0.09 min) is not sufficient for 
evaluation of the CytR signal. This is especially the case when the concentrations 
of cytidine in wastewater samples are 2-3 orders of magnitude larger than the 
expected environmental concentrations of CytR. The employed ZIC-HILIC column 
does not enable baseline separation of the two epimers. Nevertheless, there have 
been reported methods where RP chromatographic separation of CytR and cytidine 
is possible employing 100% aqueous mobile phase (Romanova, 1996; Wermeling, 
1989) , and other methods of CytR separation from an unidentified endogenous 
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Figure 3.3 5-fluorouracil and an interfering unknown substance in MS/MS extracted ion chromatograms on 
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Figure 3.4 
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water sample spiked with 2 µg/L 
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standard 13C15N2 uridine (tR 20.54) 
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compound, that we assume could be cytidine (Hsieh, 2007; Hsieh, 2007). The 
consequences of the presence of naturally occurring epimer of araU, uridine, are 
not as severe as in the case of CytR described above. The retention times differ by 
0.7 min resulting in a separation factor around 1.2 for spiked 2µg/L araU in SPE 
pre-concentrated hospital wastewater (Figure 3.4). 
 
Isobaric interferences of CytR, araU and 5-Fu are not of large concern in spiked 
samples with the amounts of cytostatics in microgram per liter range or higher, 
where no preconcentration by SPE is necessary (e.g. lab-scale experiments of 
removal from wastewater or ecotoxicity tests). 
 
 
3.2.4 Application 
The developed method employing clean-up and preconcentration on combination 
of the Isolute ENV+ cartridges with Speedisk H2O-philic SA-DVB disc cartridges, 
followed by separation on ZIC-HILIC column and detection by triple quadrupole 
MS with an electrospray ionization was successfully applied to hospital wastewater 
samples of the Cantonal Hospital Winterthur for monitoring concentrations of 5-
Fu, GemC and dFdU. The antimetabolite drug 5-Fu was detected in 76% of 17 
investigated samples, while for GemC and its metabolite dFdU the number of 
samples with concentrations above the limit of detection accounted for 65 % and 
88 %, respectively. Figure 3.5 shows a typical extracted ion chromatograms of the 
transitions used for quantification. Both cytostatics, 5-Fu and GemC, were detected 
only in samples of the days at which they were administered at the oncology clinic 
of the hospital. Measured environmental concentrations as well as the method 
validation parameters for the three analytes were in the low nanogram per liter 
range (Table 3.2).  
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Figure 3.5 MRM chromatograms of two cytostatics (5-Fu, GemC) and the human metabolite of GemC (dFdU) in: a) 
calibration standard in the mobile phase (7.5 µg/L – 5-Fu, GemC and dFdU); b) spiked hospital wastewater 
preconcentrated by Speedisk H2O-philic SA-DVB on top of Isolute ENV+ by a factor of 500 (spiked: 15 ng/L – 5-Fu 
and GemC, 60 ng/L – dFdU); c) hospital wastewater preconcentrated as above (calculated concentrations of 5-Fu, 
GemC and dFdU: 20.0 ng/L, 1.0 ng/L and 68.3 ng/L, respectively). 
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SPE recoveries 
600 ng/L in hospital ww  quantification 
 precision 
60 ng/L in hospital ww  
 
hospital ww sampling campaign 
 April 30 to May 8, 2007 (n= 17) 
    LOQ    run-to-run day-to-day  ND / >LOQ   maximum median  
 
absolute   
[%] 
relative     
[%]        [ng/L]    [pg] 
linear range 
[ng/L]    rsd [%] rsd [%]  [samples] [ng/L] [ng/L]  
               
5-Fu 46 ± 7 95 ± 2 5.0 12.5 4 - 1200 1.7 5.6  4 / 6 26.6 <LOQ  
GemC 79 ± 3 118 ± 18 0.9 0.9 0.5 - 1000 14.3 22.0  6 / 6 37.8 <LOQ  
dFdU 40 ± 5 54 ± 13 9.0 22.0 4 - 1200 11.4 19.7  2 / 12 838 68.3  
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Chapter 4 
Occurrence and Stability in Hospital 
Wastewater 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The most exciting phrase to hear in science, the 
one that heralds new discoveries, is not 'Eureka!' 
('I found it! ') but 'That's funny ...' 
         (Isaac Asimov) 
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4 Occurrence and Stability in Hospital 
Wastewater 
 
Hospitals are sources for pharmaceuticals and disinfectants, and can be seen, besides 
households and industries, as hotspots for the discharge of these emerging contaminants 
into the sewer network. If not degraded in the municipal wastewater treatment plants, 
they reach surface waters, with potential impact on the ecosystem and human health 
(Kümmerer, 2001). Within the top 100 active compounds list of the Swiss national sales 
data of pharmaceuticals, 18 % of the medicaments’ total volume is being administered 
in hospitals (Moser, 2007). 
Not much knowledge about occurrence of cytostatics in general is up to now available. 
Two cytostatics that are not in focus of this work, cyclophosphamide and ifosfamide, 
were previously detected in wastewater and even surface waters (Buerge, 2006), while 
5-fluorouracil was so far detected only in wastewater of an oncological clinic (Mahnik, 
2004). To expand the knowledge about occurrence of cytostatics as well as range of 
cytostatics for which occurrence data are available, this chapter describes a sampling 
campaign of 5-fluorouracil, gemcitabine and 2’,2’-difluorodeoxyuridine in a Swiss 
cantonal hospital.  
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4.1 Experimental 
4.1.1  Sampling of wastewater in a Swiss cantonal hospital  
The cantonal hospital has 415 occupied beds and produces a volume of 135 000 
m3/year or 1 m3/(bed•day) wastewater. It contains 1% out of a total of 41 215 occupied 
stationary beds within Switzerland. This number is based on statistics of major hospitals 
in 2004 (KSS, 2004) and additional calculation of beds for smaller hospitals based on 
the official hospital typology of the Swiss Federal Office for Statistics. The sampling 
location included all medical departments of interest, in particular radiology and 
oncology institutes, and excluded laboratory chemical water, kitchen and laundry 
wastewater. In case of rain events, storm water was discharged from roofs and from half 
of the hospital parking area (0.13 ha). Therefore, dry weather conditions were chosen 
for the sampling period in order to avoid sample dilution. The campaign was divided in 
three successive phases as illustrated in Figure 4.1: a one-week test phase (flow 
measurements), a 12-days sampling phase (18h- composite day-samples from 5:00-
23:00) and a one-day sampling phase (2-4 hours composite sample over 24 hours). 
Table 4.1 lists the samples in which the concentration of cytostatics was determined. 
 
The hospital wastewater flow rate profile was measured continuously during the test 
phase, using a flow meter (American Sigma 950) triggering the auto-sampler (American 
Sigma 900max). During the sampling period the average flow was 15.8 m3/h (min 4.0 
m3/h; max 205.7 m3/h). Since concentration variations are a priori unknown and 
expected to be high, samples must be collected with a flow- or volume-proportional 
mode to obtain representative composite samples. Due to the sewer depth of eight 
meters, at least 90 seconds of dead time is required between samples for back flushing 
the tube. To achieve sufficient accuracy for the volume of an individual sample, a 
minimum of 75 ml must be pumped each time. The auto-sampler was set to pump 75 ml 
 
 
 
Figure 4.1  Hospital wastewater flow rate at the sampling point during the test phase (April 18 – April 23, 2007) 
and the sampling phase (April 29 – May 10, 2007). 
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each time after 2 m3 of wastewater had passed the sampling station. This resulted in an 
average sampling interval of eight minutes. The flow in the sewer during the nights of 
the test phase was substantially higher than the flow during the day. This was caused by 
back flushing the hospital’s reverse osmosis installations. As the concentrations of 
cytostatics were presumed to be non-detectable in diluted night or even 24-hour 
composite samples, day and night samples were separated and only 18-hours day 
samples were analyzed. For the constitution of the mass flow profile over one day, nine 
2h- to 4h- composite samples were analyzed.  
 
As hospital wastewater is highly contaminated and for certain pharmaceuticals and 
pathogens up to about 100 times more polluted than municipal WWTP influents, 
considerations of full personal and instrumental safety measures are recommended for 
the work with hospital effluents (Oppliger, 2005). All instruments in contact with raw 
hospital wastewater were autoclaved or chemically disinfected when thermal 
sterilization was not applicable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2 Description of municipal WWTP and sampling 
The hospital wastewater is discharged to a municipal wastewater treatment plant 
(WWTP) which treats the wastewater of 115 000 inhabitants. The influent flow rate 
reaches 49 000 m3/d at dry weather, what is by a factor of 130 higher then the flow rate 
of the hospital. The hydraulic retention time in the WWTP amounts to 16 h, while the 
travel time of the wastewater from the hospital to the WWTP is only 1 h. On two 
successive Mondays, two 24h- composite flow proportional wastewater samples were 
taken after the primary clarifier (WWTP influent) and after sand filtration (WWTP 
effluent), both starting at 7:00 am. 
 
 
4.1.3 Analytes and analytical methods 
For the quantification of 5-fluorouracil, gemcitabine and 2’,2’-difluorodeoxyuridine in 
the Swiss cantonal hospital wastewater, an analytical method described in Chapter 3, 
employing SPE as described in Section 3.1.4.3 (Optional SPE for difficult matrix) was 
employed and a more sensitive  mass spectrometer API 4 000 from Applied Biosystems 
was used for the detection.  
 
Experiments of 5-fluorouracil, gemcitabine, uracil 1-β-D-arabinofuranoside and 2’,2’-
difluorodeoxyuridine stability in wastewater from University Hospital Aachen, 
Germany were quantified by the analytical method described in Chapter 3, employing 
 Sampling scheme  
18h-composite samples 
5:00 – 23:00 
2h- to 4h- composite 
samples 
Monday, April 30, 2007 6:55 – 9:35  
Tuesday, May 1, 2007 9:35 – 11:45  
Wednesday, May 2, 2007 12:05 – 14:25  
Thursday, May 3, 2007 14:25 – 17:05  
Friday, May 4, 2007 17:05 – 20:35  
Saturday, May 5, 2007 20:35 – 00:05  
Sunday, May 6, 2007 0:05 – 04:25  
Monday, May 7, 2007 4:25 – 07:55  
Tuesday, May 8, 2007 
Mo
nd
ay
, M
ay
 7,
 20
07
 
7:55 – 09:55  
   
Table 4.1 
Sampling scheme of the sampling 
campaign at a Swiss cantonal 
hospital: 18-hours (5:00-23:00) 
flow-proportional composite 
samples were collected during one 
week, and 2-4-hours flow-
proportional composite samples 
were collected over one day. 
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SPE as described in Section 3.1.4.2 (Isolute ENV+ method). An Applied Biosystems 
mass spectrometer, API 3 000, was used for detection. Limits of quantification of both 
analytical methods employed in this chapter are listed in Table 4.2. The differences in 
LOQs are partially due to different sensitivity of the detectors, and partially due to 
different preconcentration factors of the SPE methods. 
 
  LOQ in hospital wastewater [ng/L]  
  API 4 000 Occurrence in hospital wastewater study 
API 3 000 
Stability in hospital wastewater study  
5-fluorouracil  5 150  
uracil 1-β-D-arabinofuranoside  - 250  
gemcitabine  0.9 10  
2’,2’-difluorodeoxyuridine  9 100  
 
 
4.1.4 Stability in different wastewater matrices 
Stability tests of the target compounds were performed in the following matrices and 
conditions: 
1. fresh grab-samples of wastewater from the University Hospital Aachen, 
Germany (1 510 beds), 20°C, 100 rpm (rounds per minute), 2 µg/L 
2. filtered (GF/F glass-fiber filters) fresh grab-samples of wastewater from the 
same University Hospital, 4°C, 2 µg/L 
3. filtered (GF/F glass-fiber filters) fresh grab-samples of wastewater from the 
same University Hospital, -20°C, 2 µg/L 
4. filtered (GF/F glass-fiber filters) municipal wastewater treatment plant effluent, 
used in Chapter 5 for sorption experiment studies, 20°C, 100 rpm, 200 µg/L 
 
The unfiltered wastewater was divided into 12 Erlenmeyer flasks (50 mL in each flask) 
and spiked with 2 µg/L of cytostatics (5-fluorouracil and gemcitabine). The contents of 
the flasks were shaken in darkness in isothermal incubator (Multitron 2, Infors HT) at 
100 rpm and 20°C. Samples were taken as follows: t0 (duplicates), t30min, t1h (duplicates), 
t2h, t4h (duplicates), t8h, t18h (duplicates) and t30h. After spiking with internal standards, 
the exact time was recorded. The same procedure was applied for the metabolites (uracil 
1-β-D-arabinofuranoside and 2’,2’-difluorodeoxyuridine), which were spiked separately 
in another twelve Erlenmeyer flasks at 2 µg/L level. 
 
Stability tests at -20°C and 4°C for 2 days were performed with filtered hospital 
wastewater. The aliquots of 50 mL were spiked with 2 µg/L of cytostatics or 
metabolites (as named above) and frozen or refrigerated in 250 mL glass bottles for two 
days. After adjustment to room temperature, they were spiked with internal standards, 
preconcentrated and analyzed.  
 
Stability tests at 20°C with filtered municipal wastewater treatment plant effluent, after 
the sand filtration, were spiked with 200 µg/L of 5-fluorouracil or gemcitabine and 
agitated in isothermal incubator for 16 hours. Then they were spiked with internal 
standards and analyzed without preconcentration. 
 
Table 4.2 Limits of quantification (LOQ) of the employed analytical methods 
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4.2 Results and Discussion 
4.2.1 Occurrence in Hospital Wastewater and Correlation with Pharmacokinetic Data 
The mass flow profiles of cytostatics show high daily variations (Figure 4.2). Well 
detectable levels of all three compounds were measured between 11:00-20:30. In the 
night fractions, no parent cytostatic compound was detected above LOQ, while the 
human metabolite dFdU was observed also during the night. The measured mass flow 
profile is in agreement with the pharmacokinetic knowledge (Table 1.4). The oncology 
treatments are done during the day, and the major part of the parent compounds were 
expected to be emitted also during the day, after 1 h for 5-fluorouracil and within 6 h for 
gemcitabine. The profile of gemcitabine presents the excretion pattern of one hospitalized 
patient – the only patient treated with this substance (2’300 mg) that day – staying 
overnight (Table 4.3). Assuming a morning treatment, he excretes the gemcitabine and 
its metabolite dFdU in a first (09:35-11:45) and second period (14:25-17:05), which is 
physiologically relevant. The metabolite is excreted in higher amounts: 
dFdU-to-gemcitabine ratios are 10 resp. 3 in the two periods, which are comparable to 
the expected ratio of 6-17 in the excreted urine within the first six hours after infusion 
(Table 1.4). Longer elimination half lives for the metabolite dFdU explain the presence 
of the metabolized form and absence of the parent compound, gemcitabine in the night 
samples.    
 
 
 
 
Figure 4.2 Mass flow profile of 5-fluorouracil, gemcitabine and 2’,2’-difluorodeoxyuridine over one day (Monday, 
May 7, 2009). Points are the calculated values based on the measured concentrations within the composite 
sampling time interval. Minimum and maximum of SPE duplicates are described with the error bars.  
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Daily consumption of active substances  [mg/day] 
 5-Fluorouracil   Gemcitabine 
Ambulant 
patients 
Hospitalized 
patients 
Ambulant 
patients  
Ambulant 
patients 
Hospitalized 
patients  
(i.v.)     (i.v.) (Capecitabine tabl.) (i.v.) (i.v.) 
Mon. 30.04.2007 2'500 (3 pat.) 0 0  5'800 (3 pat.) 2'300 (1 pat.) 
Tue. 01.05.2007  0 0 0  0 0 
Wed. 02.05.2007 3'600 (5 pat.) 43 (1 pat.) 2'600 (1 pat.)  3'800 (2 pat.) 0 
Thu. 03.05.2007 1'300 (2 pat.) 43 (1 pat.) 0  0 0 
Fri. 04.05.2007  0 43 (1 pat.) 2'500 (1 pat.)  1'800 (1 pat.) 0 
Sat. 05.05.2007 0 43 (1 pat.) 0  0 0 
Sun. 06.05.2007 0 43 (1 pat.) 0  0 0 
Mon. 07.05.2007  950 (2 pat.) 43 (1 pat.) 0  0 2'300 (1 pat.) 
Tue. 08.05.2007 0 3'793 (1 pat.) 0  3'300 (2 pat.) 0 
       
Total on 9 days (mg) 8'350 (12 pat.) 4'051 (7 pat.) 5'100 (2 pat.)  14'700 (8 pat.) 4'600 (2 pat.) 
Cytostatics total consumption on 9 days = 36.8 g (31 pat.) 
 
 
4.2.2 Correlation between Consumption Data and Emissions in Hospital Wastewater  
The exact consumption amounts for the year 2006 (Table 4.4) and the exact 
consumption amounts during the sampling period and numbers of treated patients 
during that time (Table 4.3) were made available by oncology department of the 
investigated hospital. On average, 3-4 patients per day are treated in oncology with the 
investigated drugs. During the sampling period, 4 g/day of those cytostatics have been 
consumed. Compared to the average consumption in the investigated hospital in 2006, 
4.5 times less cytostatics are used.        
 
 
 Excretion rate [%] 
 
Consumption 
[g/year]  
Urine Faeces 
Calculated 
excreted amounts 
in urine and faeces 
[g/year] 
 
     
5-fluorouracil 1 623.8 10 0 
5-fluorouracil (from capecitabine) 4 518.0 0.54 0 186.8 
methotrexate 92.4 81 15 88.4 
cyclophosphamide 415.3 20 0 83.1 
carboplatin 99.8 70 0 69.9 
gemcitabine 498.4 5 0 24.9 
etoposide 49.0 50 0 24.5 
irinotecan 27.6 22 33 15.2 
ifosfamide 41.0 34 0 13.9 
cisplatin 31.5 40 0 12.6 
doxorubicin 22.0 10 45 12.1 
     
 
 
Measured emissions and the comparison to their consumption in oncology clinic during 
the sampling period are shown in Figure 4.3 and Table 4.5. The highest 5-fluorouracil 
loads of 7.5 mg/d (Wednesday) corresponds also to the highest daily consumption 
(Figure 4.3). The mass flow profile of 5-fluorouracil over the whole week correlates 
linearly with the intravenous consumption pattern (r2 = 0.975, last point rejected, Figure 
4.4). The consumption of capecitabine – the oral form of 5-fluorouracil, only 
administered to out-patients – is not detected in the hospital sewer, as it was probably  
Table 4.3. Exact consumption data from the oncology clinic of the investigated Swiss cantonal hospital over the 
sampling period. The number of treated patients is in parenthesis. 5-fluorouracil data do not include the out-patient 
treatment by pump infusion for 22 hours to 7 days. 
Table 4.4 
Cytostatics excreted in the highest 
amount in the investigated cantonal 
hospital in 2006 
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Figure 4.3. Mass flow profiles in hospital wastewater over 9 days (horizontal lines) compared to total predicted 
excreted amounts (bars) during the sampling period. Error bars of the measurement account for the analytical error 
of the duplicate measurements. Prediction of excreted amounts of 5-fluorouracile formed from oral capecitabine is 
represented by yellow bars, intravenous (i.v.) 5-fluorouracil is represented by orange bars. 
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Average 
consumption 
in sampling 
period [g/day] 
Excreted 
amount 
Duration 
of full 
excretion 
[h] 
Predicted 
load 
[g/day]  
Measured 
average 
load    
(min-max) 
[g/day] 
Overall 
uncertainty 
of measured 
load  [%] 
Average 
recovery in 
hosp. sewer 
(min-max) [%] 
5-fluorouracil 1.38 10% (2-98%) 6 
0.14 
(0.03-1.23) 
0.0021 
(0-0.008) 74-112% 
1.1 
(0-3) 
gemcitabine 2.14 5% (1-10%) 6 
0.11 
(0.02-0.21) 
0.0013 
(0-0.01) 86-123% 
1.4 
(0.1-6) 
2’,2’-difluorodeoxyuridine 2.15* 10% (29-86%) >24 
1.29 
(0.62-1.85) 
0.058 
(0.007-0.215) 20-123% 
3.7 
(0.7-11) 
        
 
 
 
excreted entirely in patients’ households. Moreover, the urinary excretion rate of 
5-fluorouracil after administration of capecitabine is about 20 times smaller then for the 
intravenous application.  During the last sampling day no 5-fluorouracil was detected, 
even though, there should have been an input. However, this input is predicted from the 
treatment of one single hospitalized patient (Tab. 4.3), who might not have excreted into 
the toilet of the hospital for personal reasons.  
 
For gemcitabine and its metabolite, a weaker correlation exists between measured loads 
and the consumption (Fig. 4.3). Measurable concentrations were found when a 
treatment took place, and whenever gemcitabine is present, also dFdU was found. The 
highest load of 9.7 mg/d for gemcitabine (last sampling day) was found when also a 
relatively high daily consumption occurred. Such high variations of mass loads of 
cytostatics in hospital wastewater were also observed in an Austrian study (Mahnik, 
2007) and are caused by the low number of patients receiving chemotherapy. In average 
over the 9 days sampling period, the amount of 5-fluorouracil detected corresponds to 
1.1% of the excreted quantity; for gemcitabine 1.4% of excretion, and for its metabolite 
dFdU 3.7% of excretion (Tab. 4.5).  
 
 
 
 
Table 4.5. Calculated average emission of drugs in cantonal hospital during sampling period and comparison with 
measured emission. For 5-fluorouracil only i.v. applications was considered. The consumption of dFdU was set 
equal to the consumption of gemcitabine considering the molecular weight difference*.Predicted loads were 
calculated based on the consumption and excretion, not including the consumption by out-patients. Overall 
uncertainties account for analytical, sampling and flow-measurement uncertainty and were calculated for each 
day: minimum-maximum are given. Average, minimum and maximum recoveries were calculated based on 
measured load relative to the predicted load for each day. 
 
Figure 4.4 
Linear correlation between the 
intravenous consumption of 5-Fu 
at the hospital and the measured 
emission of this compound in 
hospital wastewater. The point of 
the last Tuesday was rejected 
(x,y)=(0 mg/day, 3793 mg/day). 
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There might be several reasons for the recoveries below 5% of the predicted load: 
- excretion rates vary from patient to patient (Table 4.5)  
- the oncology department provides a high amount of ambulatory treatments: for 
5-fluorouracil, 63% were out-patients and 67% of the total quantity is 
administered to out-patients; for gemcitabine, the percentages are slightly 
higher (80% resp. 76%). Therefore, only about 30% of the administered dose is 
fully excreted on-site into the hospital sewer, remaining 70% is excreted in the 
hospital only partially.  
- relatively high sampling uncertainty occurred due to the sampling procedure 
and low number of treated patients in the hospital, as described in detail in 
(Weissbrodt, 2009). Because only a few patients are contributing to the daily 
load, the chance that at average sampling frequency of 8 minutes, some toilet 
pulses were missed is high and an uncertainty of up to 120-130% was 
calculated. This high sampling uncertainly is causing the large overall 
uncertainties listed in Tab. 4.5.  
- not much is known about stability of the target cytostatics in wastewater and 
published data on biodegradability of 5-fluorouracil differ (Tab. 1.6) 
 
A comparison for 5-fluorouracil can be done to the study performed by (Mahnik, 2004) 
Vienna University Hospital. They sampled wastewater directly from the oncology in-
patient ward fed exclusively by 3 toilets and 3 showers (used by 18 oncology patients). 
The concentrations of 5-fluorouracil were as high as 124 µg/L and loads recovered were 
in line with calculated loads when considering an excretion rate of 2%. In our study, 
when using a 2% excretion rate (instead of the average rate of 10% used for our 
calculation, Tab. 4.5), 5.5% of the expected excreted amount of 5-fluorouracil is 
recovered in the hospital sewer.  
 
Apart from hospital wastewater, we analyzed also influent and effluent of the receiving 
municipal wastewater treatment plant. Target cytostatics were neither present above 
limit of quantification in the 24-hours composite samples of the municipal wastewater 
treatment plant influent nor effluent. This is for 5-fluorouracil in accordance with the 
previously published study (Tauxe-Wuersch, 2006), Table 1.4. 
 
4.2.3 Stability Studies 
To obtain information on stability of the target compounds, and confirm or disprove one 
of the above stated hypothesis for explanation of losses in material balances of 
cytostatics in hospital wastewater, tests were performed in different matrices and at 
different conditions as described in section 4.1.4.  
 
Filtered hospital wastewater samples stored at -20°C are stable and contain after 2 days 
89, 98, 93 and 95% of spiked amount (2 µg/L) of 5-Fu, araU, GemC and dFdU 
respectively (dashed blue lines in Fig. 4.5). No decrease of spiked concentration within 
10% was also observed for the above analytes when the filtered samples were stored for 
2 days at 4°C. The same results were obtained for 200 µg/L spiked 5-Fu and CytR at 
20°C for 24 hours in filtered matrix used for the sorption experiments described in 
Chapter 5. 
 
The four investigated analytes, 5-Fu, araU, GemC and dFdU, showed to be unstable in 
raw hospital wastewater at the temperature relevant for wastewater in a sewer system 
(Figure 4.5). As the figure shows, in case of 5-Fu and GemC, we can speak of first order 
degradation reaction. The plot of araU shows slight increase in concentration within the  
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1st order kinetics 
    dc/dt = -k * c 
k               
[h-1] r
2 t1/2                 [h] 
steady state      
[h] 
5-Fu 5-fluorouracil 0.68 0.9913 1.0 5 
araU uracil 1-β-D-arabinofuranoside 0.12 0.9943 5.6 28 
GemC gemcitabine  1.05 0.9737 0.7 3 
dFdU 2’,2’-difluorodeoxyuridine 0.28 0.9618 2.5 13 
            
      
 
 
first 5 hours, which could be caused by presence of CytR in the hospital wastewater 
metabolizing into araU. This assumption was not confirmed. In case of dFdU, the first six 
points fit the curve of the first order kinetics, but the concentration stays on a threshold value 
and does not decrease to zero. The decrease in concentration is faster for cytostatics than 
for metabolites.  The half-times are around 3-5 times lower for cytostatic then for 
metabolites, as well as the time when steady state is achieved (five half-times). 
 
Figure 4.5 Stability tests of four target compounds in raw hospital wastewater at +20°C (symbols), filtered hospital 
wastewater at -20°C (dashed line), and first order kinetics fits (solid line). Limits of quantification are 8, 13, 1 and 
5% of spiked concentration 2 μg/L of 5-Fu, araU, GemC and dFdU, respectively. 
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The human metabolite of gemcitabine, dFdU, was found to be formed from gemcitabine 
in the raw hospital wastewater and its concentration was further decreasing after 
showing maximum at approximately 1.5 hours after the start of the experiment. 
Assuming that dFdU is not the only transformation product of GemC: 
 
⎯⎯ →⎯⎯→⎯⎯⎯ ⎯← dFdUmetmet kkk dFdUGemC 12  
 
and setting the differential equations: 
 
)(*)()(*)( 21 GemCckkGemCckdt
GemCdc
metmetGemC +−=−=                                    (1) 
 
)(*)(*)( 1 dFdUckGemCckdt
dFdUdc
dFdUmet −=                                                     (2) 
 
the data of dFdU formation and eventual decrease (Fig. 4.5c) were fitted using 
Modelmaker Version 4 software and the rate constant of dFdU formation, kmet1 = 0.35 h-1, 
was calculated. The rate constant of gemcitabine is equal to the sum of rate constants of 
dFdU and the unknown metabolite(s) (kmet2 = 0.70 h-1). The processes involved have 
biological transformation character, and it can be theorized that the same processes are 
also likely for 5-fluorouracil. Decrease of the concentration due to sorption to 
suspended solids is due to low Kow of the target compounds not likely.  
 
The literature reported stability of gemcitabine and dFdU in urine under refrigerated 
conditions was at least 1 month and at room temperature was at least 1 week (Freeman, 
1995). In the study at Vienna university hospital, 5-fluorouracil was reported to be 
stable in wastewater at -20°C for 28 days and for at least 7 days at 4°C and room 
temperature (Mahnik, 2004). If the reported stability tests were performed in filtered 
wastewater, they are in accordance with our results. In another publication of the same 
research group (Lenz, 2007) it is reported, that even though 5-Fu was detected in the 
oncology ward wastewater in concentrations up to 120 μg/L, no 5-Fu above the 
detection limits was detected in the in-flow of the MBR-system, witch was fed by a 
1 000-L tank with retention of approximately 24-hours. This report is fully in agreement 
with our results. On the other hand, there is a contradiction between our results and the 
results published in another study (Kummerer, 1997), where 5-fluorouracil was not 
bio-degraded at all and gemcitabine was degraded to 50%  in ready biodegradability, as 
well as inherent biodegradability tests with concentrations in mg/L range (Tab. 1.6). 
The biodegradation rate in the study was measured by non-specific parameters. 
  
Our results described in this section indicate that the main reason for the recoveries in 
hospital wastewater below 5% of the predicted load of cytostatics in the wastewater 
revealed in sections 4.2.1-4.2.1 lays in fast biodegradability of the target compounds in 
unfiltered raw wastewater. Collecting 18-hours composite sample from 5:00-23:00 
implies that the sample is unfiltered for approximately 26 hours from the beginning of 
the sampling until next morning when it is transported to the laboratory. Within that 
time, as the results depicted in Figure 4.5 show, are most of the target compounds 
degraded. 
 
4.2.4 Environmental Risk Assessment 
Predicted environmental concentration (PEC) in surface water from the measured 
concentration in the hospital wastewater was in this study estimated for two cases: (1) 
Case A assumes that the concentrations measured at hospital sewer are the only source 
of target compounds into surface waters; (2) Case B assumes that the concentrations 
measured at hospital sewer are 20% of target compound input into surface waters.  
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Further, as depicted in Figure 4.6, it accounts for:  
- 100 times dilution of the hospital wastewater before it enters municipal 
wastewater treatment plant. In the case of the Swiss cantonal hospital and the 
receiving municipal WWTP the dilution factor is 130 (average flows are 15.8 
m3/h and 49 000 m3/d respectively). 
- no elimination in the municipal WWTP. Although this is a cautious “worst 
case” scenario as the target compounds are biodegradable and unstable in raw 
wastewater (Table 1.6, Figure 4.5).  
- 10 times dilution of the WWTP effluent by discharge to the receiving surface 
water. This is the case when a treatment plant discharges into a small river. 
 
 
 
 
The exposure data of the target cytostatics in the aquatic compartment reported here 
were related to the toxicity data of the most sensitive test organism from the test 
systems listed in the table 1.5. The predicted no effect concentration (PNEC) in surface 
waters was obtained by applying a conservative assessment factor of 100 to no observed 
effect concentration (NOEC). The choice of an assessment factor influences greatly the 
final results of the risk assessment. Factors of 10-1000 are usually employed, depending 
on the degree of uncertainty in the extrapolation from the test data on a limited number 
of species to the actual environment. The “Guideline on the Environmental Risk 
Assessment of Medicinal Products for Human Use” published by EMEA (European 
Medicines Agency) in 2006, recommends in the Tier A when using long-term toxicity 
tests to employ an assessment factor of 10, accounting for inter-species variations of 
differences in sensitivity, intra-species variability, and laboratory data to field 
extrapolation.  
 
The risk quotients PEC/PNEC calculated in Table 4.6 are protective and environmental 
impact of 5-fluorouracil, gemcitabine and 2’,2’-difluoro-deoxyuridine seems to be of 
minor importance. Nevertheless, cytostatics are special group of pharmaceuticals with 
carcinogenic potency which implies that in general no threshold values for lowest effect 
concentrations can be estimated. Until data with specific tests and end-points designed 
especially for this class of pharmaceuticals are available, precautionary principle should 
be applied. 
 
 NOEC     [ng/L] 
PNEC                   
[ng/L]                   
assessment factor: 100 
PEC (surface water) [ng/L] 
 
       Case A                      Case B 
PEC / PNEC   
 
       Case A                      Case B          
5-fluorouracil 1 .104 1 .102 0.03 0.14 3 .10-4 1 .10-3 
gemcitabine >1 .106 >1 .104 0.04 0.19 <4 .10-6 <2 .10-5 
2’,2’-difluorodeoxyuridine >1 .106 >1 .104 0.88 4.20 <8 .10-5 <4 .10-4 
 
Figure 4.6 
Schematic drawing of factors and 
flows considered in calculation of 
the predicted environmental 
concentration (PEC) in surface 
water from the measured 
environmental concentration (MEC) 
in a Swiss hospital wastewater. 
 
Table 4.6 Environmental risk assessment 
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Chapter 5 
Removal by Activated Carbon 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All science is either physics or stamp collecting. 
         (Ernest Rutherford) 
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5 Removal by Activated Carbon 
 
The development and application of more efficient and cost-effective advanced 
wastewater treatment steps is presently an intensively discussed issue (Jones, 2007; 
Joss, 2008). Post-treatment based on processes such as adsorption to activated 
carbon, membrane processes or ozonation might soon become common also in 
wastewater, not only drinking water treatment. Adsorption is widely used for water 
purification and has been studied for decades. Most of the research in the field is 
focused on apolar (hydrophobic) or moderately polar adsorbates, as the process is 
the most effective for those compounds. Generally, compounds with a low 
octanol/water partitioning coefficient adsorb rather poorly to activated carbon from 
the water phase. Despite low adsorption capabilities, the potential of polar 
micropollutant adsorption can be exploited in wastewater treatment processes, at 
least to a certain extent, when the process is applied to non-polar compounds.  
This chapter aims to study the removal of polar compounds, such as the target 
cytostatics, from wastewater by sorption to powdered activated carbon. To 
investigate the sorption process, laboratory scale batch experiments were 
conducted to evaluate the adsorption kinetics and isotherm data of 5-fluorouracil 
and cytarabine on two powdered activated carbons (Norit SAE Super and 
Activated Lignite HOK Super). The influence of the solution chemistry (pH and 
ionic strength) and other parameters (temperature and competing background 
organic compounds) on adsorption was also analyzed. Further, the adsorption 
capacity of carbon at different initial micropollutant concentrations was estimated 
by a modeling approach that can be used in wastewater treatment to prediction the 
minimum powdered activated carbon doses required for elimination of polar 
adsorbates to a certain concentration c1 (e.g. calculation of the carbon dose for 
removal of the polar micropollutant down to 30 ng.L-1), or a certain c1/c1,0 ratio 
(e.g. calculation of the carbon dose for 95% removal of the polar micropollutant). 
Interactions between the adsorbent and adsorbate are primarily controlled by non-
specific dispersive interactions (e.g. van der Waals interactions), although 
electrostatic interactions between ionic adsorbates and charged adsorbent surface 
are also present. Besides the ionization state of the adsorbate, surface charge of the 
adsorbent also plays a role in sorption processes (Newcombe, 2006). The surface of 
activated carbon is always charged due to surface functional groups. The point of 
zero surface charge (pHPZC) determines the pH at which the net surface charge of 
the carbon equals zero, since at this pH there are as many positively as negatively 
charged functional groups. Below the pHPZC the carbon surface is mostly positively 
charged. Despite pHPZC being crucial characteristic of each adsorbent, the values 
for commercially available powdered activated carbons are not available. For the 
two studied adsorbents, Norit SAE Super and Activated Lignite HOK Super, the 
pHPZC values were determined experimentally in this study. 
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5.1 Experimental 
5.1.1 Adsorbents 
Two commercially available powdered activated carbons were tested: Norit SAE 
Super (Norit, Amersfoort, The Netherlands) and Activated Lignite HOK Super 
(RWE Power - Rheinbraun Brennstoff, Frechen, Germany). The adsorbents were 
dried in an oven for 3 hours at 150°C (ASTM, 2003) prior to storage in glass 
bottles with Teflon-coated screw caps. The pH of the point of zero surface charge 
(pHPZC) was established using the mass titration method (Li, 2002). Table 5.1 
summarizes the properties of the studied adsorbents. 
 
 
 pHPZC Surface area [m2/g] 
Particle size  d50 
[µm] 
Raw 
material 
Activation 
method Supplier 
Price 
[€/t] 
SAE Super 9.8 1300 15 peat/wood steam Norit 1200 
HOK 10.0 300 24 lignite steam RWE 350 
 
5.1.2 Adsorbates 
Reference compounds 5-fluorouracil and cytarabine were purchased from Sigma-
Aldrich (Seelze, Germany). The 200 mg.L-1 stock solutions were prepared in 
Millipore water and stored in the dark at 4°C for up to 3 weeks. Analysis of the 
target adsorbates by HPLC-MS/MS was performed on an API 3000 (Applied 
Biosystems, Foster City, CA) as described in the Chapter 3. The method involved a 
2 µL injection of filtered aqueous sample diluted to 50% with acetonitrile. Labeled 
internal standards, [15N2] 5-fluorouracil and [13C3] cytarabine, were used for quality 
assurance of the analysis. Limits of quantification without SPE were 0.5 and 1 
µg.L-1 for 5-fluorouracil and cytarabine, respectively. SPE preconcentrated samples 
could be quantified for concentrations above 15 and 3 ng.L-1 for 5-fluorouracil and 
cytarabine, respectively.   
5.1.3 Solvents 
All solvents for the adsorption experiments were handled in organic-solvent-free 
and surfactant-free glass or polyethylene. Wastewater treatment plant (WWTP) 
effluent used for the experiments originated from the municipal wastewater 
treatment plant in Aachen Soers, Germany. Approximately 100 L of treatment 
plant effluent were collected, thoroughly mixed and stored in 2L bottles at -20°C 
until they were thawed at room temperature and filtered with GF/F filter 
(Whatman, Dassel, Germany) prior to each experiment. The pH of this WWTP 
effluent was 7.8 and the total organic carbon concentration was 5 mg.L-1. 
 
Concentrated WWTP effluent was obtained by a four-fold concentration of WWTP 
effluent by nanofiltration membrane with a molecular weight cut-off of 200 
Daltons. The concentrated effluent originated from the same wastewater treatment 
plant as the WWTP effluent described above but was collected at a different time 
point. Total organic carbon concentration in the concentrated effluent was 20 mg.L-1. 
Table 5.1. Characterization of the adsorbents. Values of pHPZC were determined in this study, remaining data 
provided by suppliers. 
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Single solute isotherms were performed in 5 or 100 mM phosphate buffers with 
pHs of 6.2, 7.8 or 9.6. The 5 mM phosphate buffer pH 7.8 was carefully selected, 
so that it had the same ionic strength and pH as the above described WWTP 
effluent after carbon additions. 
 
5.1.4 Adsorption kinetics and isotherm set-up 
Kinetics experiments for each adsorbate were performed separately in 1L 
Erlenmeyer flasks containing a given amount of carbon. The higher and lower 
doses of Activated Lignite HOK Super were 500 and 50 mg.L-1 for both 
adsorbates. The higher dose of Norit SAE Super was 220 mg.L-1 for 5-fluorouracil 
and 100 mg.L-1 for cytarabine. The lower dose of Norit SAE Super was 40 mg.L-1 
for 5-fluorouracil and 20 mg.L-1 for cytarabine. Subsequently, 400 mL of WWTP 
effluent with 200 or 0.8 µg.L-1 of a single adsorbate was transferred into the flasks. 
Two flasks for each kinetics curve construction were used to obtain measurements 
in duplicate. The contents of the flasks were shaken in isothermal incubators 
(Multitron 2, Infors HT) at 100 rpm (rounds per minute) and 20°C. At the time 
point before the addition of wastewater to the activated carbon and in the course of 
up to 22 hours, samples of 1 mL were taken by syringe and were immediately 
filtered by a syringe filter (IC Acrodisc, 45 µm, Pall). The sum of all of the 
withdrawn samples decreased the total volume by no more than 2.5%. From the 
filtrate, 0.5 mL was transferred into HPLC vials, diluted with acetonitrile and 
spiked with an internal standard to 100 µg.L-1. The liquid phase concentration of 
the adsorbate was measured and the solid phase concentration of the powdered 
activated carbon was calculated by a mass balance. 
 
Adsorption isotherm experiments for each adsorbate were performed separately in 
250 mL Erlenmeyer flasks containing different amounts of carbon. Each amount of 
carbon was weighed twice to obtain the measurements in duplicate; two blanks 
with no added carbon were included with each isotherm experiment. Subsequently, 
100 mL of WWTP effluent or buffer with 200 or 0.8 µg.L-1 of a single adsorbate 
was transferred into the flasks. The content of the flasks was shaken in isothermal 
incubators at 100 rpm and 4 or 20°C for 16 hours. Samples were filtered and 
analyzed as described above. 
 
5.1.5 Adsorbate removal prediction 
Prediction of the adsorbate removal from the same wastewater matrix at different 
initial adsorbate concentrations was performed using a pseudo-single solute 
isotherm, derived from a simplification of ideal adsorbed solution theory (IAST), 
11111 /1
1
/)1(
10,1
/)1(
0,22111 )()/(
nnnnn ccccnnKq −− −=  (1) 
and the direct link between relative removal and the carbon dose 
11 /1
10,1
)/11(
0,2
11
2 )1/( nnc cccKn
nc −= −  (2)
 
both as described in Qi et al., 2007. Subscripts 1 and 2 refer to the micropollutant 
and equivalent background compound (EBC), respectively. K is the Freundlich 
isotherm coefficient [(µg.mg-1)(µg.L-1)-(1/n)], 1/n is the Freundlich isotherm 
exponent [dimensionless], c is the aqueous-phase concentration [µg.L-1], q is the 
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solid-phase concentration [µg.mg-1], and initial concentrations are represented by 
the subscript 0. 
 
Experimental data derived from WWTP effluent on Norit SAE Super were used for 
calibration of the model and were fitted by a nonlinear regression routine in RGui, 
version 2.6.2, to Eq. (3), 
111 /1
1
/)1(
10,11 )(
nnn cccAq −−=  (3) 
which is the pseudo single-solute isotherm (Eq. (1)) with the term 
11 /)1(
0,2211 )/(
nncnnK − substituted by A. The two EBC parameters, c2,0 and 1/n2, in the term A 
are correlated and their individual values can not be resolved independently (Qi, 
2007). The parameters A and n1 determined by Eq. (3), were used in Eq. (4), 
derived from the Eq. (2), 
1/1
1
0,1 )1(1 nc c
c
A
c −=   (4) 
to calculate the carbon doses for any initial adsorbate concentration c1,0 and a set of 
c1 concentrations in the range (c1,010-4; c1,0). From the obtained data, adsorptive 
capacities q1 were calculated, 
ccccq /)( 10,11 −=   (5) 
and plots of q1=f(c1), predicting the adsorbate removal at different initial 
concentrations, were constructed. 
 
 
 
 
5.2 Results and Discussion 
5.2.1 Adsorption characteristics on two activated carbons in wastewater 
To illustrate the extent of the difference in adsorption of the target hydrophilic 
micropollutants, 5-fluorouracil and cytarabine, and two other selected hydrophobic 
compounds, bisphenol A and 17-α-ethinylestradiol, Figure 6.1 compares adsorption 
of the four compounds to Norit SAE Super, under the same experimental set-up 
and conditions and from the same WWTP effluent with pH 7.8 (Lehnberg, 2009). 
Fig 5.1 illustrates the difference in polarities of the 4 adsorbates. Assuming that the 
log Dow of 5-fluorouracil is at the working pH, due to its ionization, lower than log 
Dow of cytarabine, it can be observed that the sorption behavior corresponds to 
what is expected from octanol/water partition coefficients. The apolar 
17-α-ethinylestradiol adsorbs most readily, followed by bisphenol-A, cytarabine 
and 5-fluorouracil. To remove 90% of the adsorbates from WWTP effluent, 7, 15, 
65 and 160 mg.L-1 of Norit SAE Super is required, respectively. Simplifying the 
comparison, to remove polar compounds to the same extent requires an 
approximately one order of magnitude higher carbon doses in the wastewater 
treatment process. When 30 mg.L-1 of Norit SAE Super is applied to the WWTP 
effluent, which is a carbon dose sufficient to remove nearly all of the two apolar 
adsorbates, the remaining percentage of cytarabine and 5-fluorouracil are about 35 
and 70%, respectively.  
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3 
The single solute isotherms of the same four adsorbates in 5 mM phosphate buffer 
fit well to a Freundlich isotherm. The Freundlich parameters (Tab. 5.2) of the 
isotherms obtained on the second tested carbon, Activated Lignite HOK Super, 
reveal that the difference in the Freundlich coefficient (KF) representing sorption 
capacity of Activated Lignite HOK Super, is one order of magnitude lower for the 
polar adsorbates when compared to the apolar ones. The Freundlich exponent, 
determining the slope of the linear curve, is higher for polar then for apolar 
adsorbates, resulting in a steeper slope for polar adsorbates which indicates bigger 
differences between higher and lower carbon concentrations. 
 
q = KF.c1/n KF [(μg.mg-1)( μg.L-1)-(1/n)] 1/n R2 
Range c/c0 
[%] 
5-fluorouracil 0.55 0.43 0.996 7-76 
cytarabine 0.67 0.43 0.987 5-72 
17-α-ehynylestradiol 5.25 0.28 0.953 1-46 
bisphenol A  5.24 0.20 0.921 4-48 
 
 
Figure 5.1 further proves that the percentage of adsorbate removal is independent 
of the initial adsorbate concentration, as shown for the two concentrations of 
cytarabine and 5-fluorouracil, 200 and 0.8 μg.L-1. This allowed for performing all 
subsequent experiments at an initial concentration of 200 μg.L-1, avoiding sample 
preconcentration prior to quantitative analysis. For the tested micropollutants, the 
proportionality between the powdered activated carbon (PAC) capacity and the 
initial adsorbate concentration was at levels not influencing the adsorption of EBC 
previously shown by Knappe et al., 1998 to be consistent with the IAST 
(Sontheimer, 1985). The necessary assumptions are that the adsorbent surface 
loading is dominated by the competing EBC (q2»q1) and the Freundlich isotherm 
exponents of both, micropollutant and EBC, are of the same range (0.1-1) (Knappe, 
1998). The first assumption holds for the poorly adsorbing highly polar 
micropollutants well. And as the typical Freundlich isotherm exponents are in the 
range 0.2-1 (Qi, 2007), it can be assumed that the second assumption also holds. 
carbon dose [mg.L-1]
0 50 100 150
c/
c 0
0.0
0.5
1.0Figure 5.1 Polar versus apolar adsorbate. 
Comparison of fraction adsorbate 
remaining at equilibrium as a 
function of carbon dose for polar 
5-fluorouracil, and cytarabine versus 
apolar 17-α-ethinylestradiol, and 
bisphenol-A  from WWTP effluent 
on Norit SAE Super.  
Experimental conditions: WWTP 
effluent spiked with 200 μg.L-1 
(open or light solid symbols) or 0.8 
μg.L-1 (dark solid symbols) of a 
single adsorbate, pH 7.8, 20°C, 
100 rpm, 16 h contact time. 
○●5-fluorouracil, ▽▼ cytarabine, 
◇17-α-ethinylestradiol,                        
□  bisphenol-A 
 
Table 5.2. Freundlich single solute isotherm parameters of HOK in 5mM phosphate buffer pH 7.8, c0=200μg.L-1, 
t=20°C, 16 h contact time, 100 rpm. Isotherms are fitted at range c/c0 at which pH was not influenced by the 
adsorbent addition. 
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Kinetic experiments are regarded as a prerequisite for isotherm studies, providing 
the information about the equilibrium times. Further, they are of much interest 
when designing a wastewater treatment process. Figure 5.2 shows the sorption 
kinetics of 200 μg.L-1 of 5-fluorouracil and cytarabine in the WWTP effluent, when 
two doses of Activated Lignite HOK Super and Norit SAE Super were applied. 
The higher and lower doses were selected so that they remove approximately 95 
and 40% of the adsorbate, respectively. There is a difference between the sorption 
rates at different carbon doses (Fig. 5.2), with longer equilibration times needed for 
lower carbon doses. This is consistent with the assumption that adsorption rate is 
directly proportional to the concentration of vacant surface sites. The kinetics of 
both target adsorbates is comparable and is similar on both studied adsorbents. 
Contact times above 5 hours yield results close to equilibrium, for higher as well as 
for lower carbon doses, and would be recommended contact time for the proposed 
wastewater treatment applications. An equilibration time of 16 hours was applied 
in the adsorption isotherm set-up. The kinetics of 0.8 μg.L-1 5-fluorouracil and 
cytarabine in WWTP effluent provided the same conclusions (data not shown). 
 
Experimental adsorption isotherms of both polar adsorbates from WWTP effluent 
to Activated Lignite HOK Super and Norit SAE Super are depicted in Figure 5.3. 
Norit SAE Super provides higher adsorption capacities for both target adsorbates 
when compared to Activated Lignite HOK Super, which is in accordance with the 
different surface areas of the two adsorbents (Table 5.1). The powdered activated 
carbon doses required to achieve 90% removal of the target polar adsorbates are 3 
to 5-fold higher for Activated Lignite HOK Super than for Norit SAE Super, while 
the surface area is 4.3-fold lower. The difference in the adsorption capacities 
between cytarabine and 5-fluorouracil is more pronounced on Norit SAE Super 
than on Activated Lignite HOK Super. Affinities of the two compounds are equal 
on Norit SAE Super, which is not observed on Activated Lignite HOK Super. Non-
linearity in the plot at the region of high surface concentrations is apparent on both 
tested adsorbents for cytarabine as well as 5-fluorouracil and its possible cause is 
discussed further in section 5.2.2.4.  
 
carbon dose [mg/L]
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A
BFigure 5.2 
Adsorption kinetics of 5-fluoro-
uracil (circles), and cytarabine 
(triangles) from WWTP effluent on 
Norit SAE Super (A), and Activated 
Lignite HOK Super (B) at two 
carbon doses: higher dose (light 
color), lower dose (dark color). 
Experimental conditions: spiked 
200 μg.L-1 of a single adsorbate, 
pH 7.8, 20°C, 100 rpm.  
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5.2.2 Influence of various parameters on adsorption to activated lignite HOK Super  
5.2.2.1 Influence of the solution pH 
 
The Solution pH, ionic strength, adsorbent pHPZC, and adsorbate pKa are the key 
factors controlling the Coulombic adsorbent-adsorbate interactions (Newcombe, 
2006). Figure 6A shows the adsorption isotherms of 5-fluorouracil and cytarabine 
on Activated Lignite HOK Super from 0.1 M phosphate buffer at three different pH 
values. In case of 5-fluorouracil, raising the pH above 6 increases the fraction of 
negatively charged species (Figure 5.4) and it can be observed that the adsorption 
capacity of Activated Lignite HOK Super at pH 9.6 is considerably lower than at 
lower pHs. At the same time, increasing the pH also influences the ionization state 
of the carbon, increasing the number of negatively charged functional groups and 
thus the possibility of repulsion. However, the surface charge stays though on 
average positive until the solution pH reaches the pHPZC of the carbon, in the case 
of Activated Lignite HOK Super pH 10.0 (Table 5.1). Varying pH from 6.2 to 9.6 
has no influence on the adsorption characteristics of cytarabine, as the adsorbate is 
always in its neutral form in this range.  
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Figure 5.4 
Changes in ionization state of 
5-fluorouracil, cytarabine and 
Activated Lignite HOK Super, one 
of the tested powdered activated 
carbons (PAC), with changing pH of 
the solution. The arrows indicate 
the pH at which the adsorption 
experiments were performed. 
 
Figure 5.3 
Adsorption isotherms of 5-fluoro-
uracil (circles), and cytarabine 
(triangles)  from WWTP effluent on 
Norit SAE Super (open symbols), 
and Activated Lignite HOK Super 
(solid symbols).  
Experimental conditions: spiked 
200 μg.L-1 of a single adsorbate, 
pH 7.8, 20°C, 16 h contact time, 
100 rpm.  
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The addition of different carbon doses into unbuffered solution results in a gradual 
change in the pH of the system. Performing the adsorption isotherm experiment on 
Activated Lignite HOK Super in Millipore water (data not shown) resulted in a 
curve overlapping the plot of pH 6.2 in Figure 5.5A when the pH was in the range 
of 5-8 (low carbon doses) and the plot of pH 9.6 when the pH was in the range of 
9.5-10.5 (high carbon doses). The part of the curve in between those two ranges 
had a steep slope and represented carbon doses 150-300 mg.L-1. This implies the 
fact that isotherms in unbuffered systems without pH control might lead to 
substantial errors, as the possible change of solution pH after addition of increasing 
doses of carbon influences both the ionization state of adsorbate and the net surface 
charge of the carbon. 
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pH 9.6: Freundlich  1/n=0.34, K=0.28
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1
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pH 6.2: Freundlich  1/n=0.36, K=0.75
pH 7.8: Freundlich  1/n=0.48, K=0.43
pH 9.6: Freundlich  1/n=0.03, K=3.27
5-Fu
CytR
5-Fu
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carbon dose [mg/L]
1
10
5 mM: Freundlich 1/n=0.43, K=0.55
100 mM: Freundlich  1/n=0.36, K=0.51
c [μg.L-1]
100
q 
[ μg
.m
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1 ]
1
10
5 mM: Freundlich  1/n=0.43, K=0.67
100 mM: Freundlich  1/n=0.48, K=0.43
5-Fu
CytR
carbon dose [mg/L]
1
10
4°C: Freundlich  1/n=0.15, K=1.87
20°C: Freundlich  1/n=0.36, K=0.51
c [μg.L-1]
100
q 
[ μg
.m
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1 ]
1
10
4°C: Freundlich  1/n=0.13, K=2.73
20°C: Freundlich  1/n=0.48, K=0.43
5-Fu
CytR
pH
matrixtemperature
ionic strength
30 50 200
20 50 200
A
C
B
D
5030
5 mM phosphate buffer
WWTP effluent
concentrated WWTP effluent 
200
 
Table 5.5. Effects of pH, ionic strength, temperature and matrix compounds on adsorption isotherms of 
5-fluorouracil (circles), and cytarabine (triangles) on Activated Lignite HOK Super. Freundlich isotherm coefficients 
are listed for the single solute isotherms in a phosphate buffer  (q = K.c1/n, K is listed in (μg.mg-1)( μg.L-1)-(1/n)). 
Experimental conditions: (A)-(D): spiked 200 μg.L-1 of a single adsorbate; 100 rpm; contact time 16 h.  
(A): 100 mM phosphate buffers; pH 6.2, 7.8 or 9.6; 20°C. (B): 5 or 100 mM phosphate buffers; pH 7.8; 20°C. (C): 
100 mM phosphate buffer; pH 7.8; 4 or 20°C. (D): 100 mM phosphate buffer, WWTP effluent or concentrated 
WWTP effluent; pH 7.8; 20°C. 
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5.2.2.2 Influence of ionic strength 
 
To determine the effect of the solution ionic strength on the adsorption process, the 
adsorption isotherms of 5-fluorouracil and cytarabine were derived from two 
buffers of different molarity at pH 7.8 (Figure 5.5B). Comparison of the 
corresponding plots shows that the increase in the ionic strength decreases the 
sorption capacity of 5-fluorouracil, while for cytarabine is the decrease apparent 
only at low surface concentrations. This is due to the different ionization state of 
the adsorbates and is in agreement with the theory presented in (Moreno-Castilla, 
2004). At solution pH 7.8, the Activated Lignite HOK Super surface charge is 
positive on average, 5-fluorouracil is partially negatively charged (less than 50%) 
and cytarabine is in its neutral form. Screening of the attractive electrostatic 
interactions between Activated Lignite HOK Super and 5-fluorouracil as well as 
when surface concentrations of cytarabine are low, is more pronounced at higher 
ionic strength conditions, resulting in lower sorption capacity. 
 
For uncharged hydrophobic compounds it was previously demonstrated that an 
increase of ionic strength can lead to a considerable increase in adsorption capacity 
(Toledo, 2005). This is partially explained due to the salting-out effect, decreasing 
the solubility of the hydrophobic solute and enhancing its adsorption. For the 
uncharged polar compounds, as the results of cytarabine show, is this is due to their 
good solubility not the case. 
 
 
5.2.2.3 Influence of temperature 
 
A study was also conducted on the temperature effects on the adsorption capacity 
of Activated Lignite HOK Super. The adsorption isotherms of 5-fluorouracil and 
cytarabine were obtained at the same experimental conditions, but different 
temperatures, at 4°C and 20°C. Figure 5.5C depicts the results showing that lower 
temperature provides more favorable conditions for the adsorption of both solutes. 
As adsorption is an exothermic process, decrease in temperature increases the 
uptake, which is also expected  from the adsorption theory (Moreno-Castilla, 
2004). It should be noted that the extent of the influence is not negligible, but 
comparable with the extent of the influence of the solution pH and ionic strength. 
 
 
5.2.2.4 Influence of competing compounds 
 
 Presence of competing matrix compounds greatly influences the adsorption of 
both polar adsorbates, as is noted on different scale of the y-axes when comparing 
plots in Figure 5.5A,B,C,D. The single solute isotherms of 5-flourouracil and 
cytarabine obtained in 5 mM phosphate buffer pH 7.8 fit the Freundlich isotherm 
model. Table 6.2 lists the Freundlich parameters of the target adsorbates. Isotherms 
in multi-compound mixture of WWTP effluent show lower adsorption capacity and 
non-linearity (Figure 5.5D). The effect is even more pronounced in the 
concentrated WWTP effluent. Generally poorly adsorbing polar compounds 
experience direct competition with natural organic matter. The competition is less 
pronounced at high carbon doses than at low carbon doses, when the number of 
sorption sites is very limited. The change in the extent of the influence is reflected 
in the non-linearity of the isotherms obtained in the WWTP effluent. 
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5.2.3 Prediction of adsorbate removal from the wastewater 
 While experimentally determined single solute isotherms of 5-fluorouracil and 
cytarabine fit the Freundlich isotherm model well, isotherms in the WWTP effluent 
have a sharp drop in q to the right of the maximum and fit well a pseudo-single 
solute isotherm in log-log q=f(c) plot (Qi, 2007). 
 
As shown and discussed in section 5.2.1., PAC capacity and the initial adsorbate 
concentration are in case of the target adsorbates in the WWTP effluent 
proportional even if the adsorption isotherms are not linear. This can be used for 
prediction of adsorbate removal from the same matrix (wastewater) at different 
initial adsorbate concentrations if the data for one initial micropollutant 
concentration are available. Figure 6.6 shows the pseudo-single solute isotherm fit 
(Qi, 2007) of the experimental data of cytarabine with an initial concentration of 
200 μg.L-1 in WWTP effluent on Norit SAE Super. No single solute isotherm data 
are required for the employed approach. The two unknown parameters from 
Eq. (3), A and n1, were determined to be 0.0486±0.0016 L.mg-1  and 2.009±0.089, 
respectively.  
 
Further, Fig.5.6 shows the predicted isotherms of cytarabine in WWTP effluent for 
initial concentrations 33, 6.2 and 0.8 μg.L-1 as well as experimental data for 0.8 
μg.L-1. Good agreement between experimental and predicted data confirms the 
suitability of Eq. (1) and (2) for such a prediction and proves that the concept of Qi 
et al., 2007 is suitable for highly polar adsorbates. This simple and powerful 
approach might be used in wastewater treatment for prediction of minimal PAC 
doses required for elimination of polar adsorbates to a certain concentration c1, e.g. 
30 ng.L-1 as depicted in Fig. 5.7, or a certain c1/c1,0 ratio. 
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5.2.4 Conclusions 
The presented study focused on the adsorption behavior of highly polar 
micropollutants with a log Dow below -0.8 and the potential of powdered activated 
carbon for their removal from wastewater. The findings can be summarized as 
follows: 
(1) Influence of various parameters on adsorption 
- Influence of the solution pH on the carbon adsorption capacity was observed to be 
relevant only for charged adsorbate and was comparable with the magnitude of the 
Figure 5.6 
Adsorption isotherm predictions 
for cytarabine on Norit SAE Super 
in WWTP effluent from municipal 
wastewater treatment plant Aachen 
Soers, Germany. Experimental 
data points for cytarabine 
concentrations 200 and 0.8 µg.L-1 
are shown as grey and black 
triangles, respectively. Solid and 
dashed lines represent model fit 
and model predictions (Qi, 2007), 
respectively. 
 
 
 
 
Removal by Activated Carbon               Chapter 5               71 
 
 
Initial cytarabine concentration [μg.L-1]
0 50 100 150 200
PA
C
 d
os
e 
pr
ed
ic
tio
n 
[m
g.
L-
1 ]
0
500
1000
1500
 
 
 
influence of ionic strength and temperature. Competing background organic matrix 
decreases adsorption capacities to much greater extent than the three above 
mentioned factors. 
- Performing isotherm experiments with different carbon doses in unbuffered 
systems (Millipore water) might lead to pH shifting and consequently substantial 
errors. This is especially the case when the pKa or pHPZC of the adsorbates are 
close to or within the working pH range. 
- Comparing the two adsorbent materials with similar pHPZC, the performance was 
corresponding with their surface areas. 
 
(2) Potential for wastewater treatment application 
- Doses of carbon sufficient to almost completely remove apolar micropollutants 
(bisphenol A and 17 α ehinylestradiol) from WWTP effluent are able to remove 
approximately 50% of highly polar micropollutants (5-fluorouracil and cytarabine). 
- Contact times above 5 hours yield results very close to equilibrium and would be 
advisable for maximum efficiency at a wastewater treatment process. 
 
(3) Prediction of the adsorption capacity at different initial micropollutant 
concentrations 
- Prediction using a pseudo single-solute isotherm for micropollutants in a 
wastewater matrix was feasible in this study, as the percentage removal of target 
micropollutants was experimentally confirmed to be independent of their initial 
concentration. The two main assumptions for IAST simplification, q2»q1 and n1≈n2, 
were found valid for the polar adsorbates of interest. 
- The pseudo single-solute isotherm equation and the explicit relation between the 
carbon dose and equilibrium removal proved to be reliable and simple tool for 
prediction of the adsorption capacity at different initial concentrations of the target 
polar micropollutants.  
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I am among those who think that science has great 
beauty. A scientist in his laboratory is not only a 
technician: he is also a child placed before natural 
phenomena which impress him like a fairy tale. 
         (Marie Curie) 
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6 Conclusions 
 
The main objectives of this work lied in: (A) developing a robust and sensitive 
analytical method for the analysis of the selected cytostatics and their metabolites in 
wastewater; (B) applying the analytical method for determination of cytostatic 
concentrations in hospital and municipal wastewater; (C) assesing the environmental 
risk caused by the selected cytostatics (and metabolites); (D) evaluating the sorption 
behavior of cytostatics to powdered activated carbon as a surrogate for the removal of 
polar micropollutants and as a potential wastewater treatment process. This concluding 
chapter summarizes to which extent the objectives were achieved, points out the 
novelties and highlights of this work, and gives a brief outlook for future work. 
 
A robust and sensitive HPLC-MS/MS method with SPE pre-concentration was 
successfully developed and validated for analysis of the selected, highly polar 
cytostatics and their metabolites in wastewater.  The limits of quantification (LOQ) 
were in low ng/L range, which is an improvement when compared to other recently 
published methods for the similar matrices. Concerning the retention mechanism studies 
investigated in parallel with the method development, this is one of the first studies that 
confirms the hypothesis that the hydrophilic interaction chromatography (HILIC) 
retention mechanism is not based solely on partitioning, but also on surface adsorption.  
 
The method was applied for the determination of two cytostatics with high consumption 
and one known human metabolite in the wastewater effluent of a Swiss hospital, along 
with the influent and effluent of the corresponding municipal wastewater treatment 
plant (WWTP). None of the measured analytes were present above the detection limits 
in any of the municipal wastewater samples, while the concentrations in hospital 
wastewater ranged between <5 and 27 or <0.9 and 38 ng/L for 5-fluorouracil and 
gemcitabine, respectively. The gemcitabine metabolite 2’,2’-difluorodeoxyuridine was 
detected in the hospital wastewater in concentrations up to 838 ng/L. To the best of our 
knowledge, gemcitabine and its urinary excreted human metabolite 2’,2’-
difluorodeoxyuridine had never been previously monitored in wastewater or any other 
compartment of the aquatic environment.  Further, this is the first study to show that 
they are present in the wastewater and that 2’,2’-difluorodeoxyuridine is a metabolite of 
gemcitabine formed not only in human body, but also in wastewater. Apart from 
measuring concentrations in the hospital effluent, the consumption data of 5-
fluorouracil and gemcitabine at the hospital were collected during every sampling day 
(number of patients and doses applied). Good correlation of 5-fluorouracil consumed 
and measured amounts (r2 = 0.975) was observed. Further, gemcitabine-to-metabolite 
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ratios were calculated from concentrations in hospital wastewater samples at the time 
periods when only one patient in the  hospital  was  treated.  The calculated ratios agree 
with  values in  urine  reported  in medical literature dealing with pharmacokinetics of 
gemcitabine. The target compounds were shown to be readily biotransformed in raw 
hospital wastewater and degraded within 5 to 30 hours, which is not the case in other 
matrices. 
 
Following the hospital wastewater screening, environmental concentrations could be 
estimated and compared with the available ecotoxicity and genotoxicity data. The 
conservative risk assessment shows that the environmental risk caused by the target 
compounds is not relevant (PEC/PNEC 10-3 - 10-6). Compounds are not stable in the 
wastewater and will be partially degraded already before reaching the wastewater 
treatment plant and fully degraded by the time they leave the treatment plant and reach 
the environment. This however does not mean that the risk assessment of other, more 
persistent cytostatics (e.g. cyclophosphamid) would provide the same results and that 
our results are valid for cytostatics as a pharmaceutical class. The future research should 
focus on defining the appropriate toxicity tests for cytostatics that would consider their 
mode of action and account for the effects they may cause in the environment due to 
their pharmacological design. Consequentially, a risk assessment with PNEC of such an 
origin can be reliably performed.  
 
Sorption to powdered activated carbon was chosen for investigation as one of the 
possible solutions for removal of cytostatics from wastewater, during the wastewater 
post-treatment process.  Batch-scale experiments elucidated sorption of 5-fluorouracil 
and cytarabine to Norit SAE Super. A 30 mg/L dose of the carbon, sufficient to remove 
completely apolar micropollutants (bisphenol A and 17-α-ehinyl-estradiol) from a 
municipal WWTP effluent, removes 25 - 65 % of the two cytostatics from the same 
matrix.  Prediction  of minimal dose of powdered activated carbon, required to eliminate   
the target compounds to certain concentration or ratio, is feasible using the pseudo single-
solute isotherm model.
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